## Nutrition Research and Practice

# Original Research

( Check for updates

OPEN ACCESS

Received: Sep 14, 2022 Revised: Nov 26, 2022 Accepted: Feb 8, 2023 Published online: Feb 24, 2023

#### <sup>§</sup>Corresponding Author: Özlem Özpak Akkus

Department of Nutrition and Dietetics, Toros University, 45 Evler Campus, Yenişehir/Mersin 33140, Turkey. Tel. +90-324-325-3300–1195 Email. dytozlemozpak@hotmail.com

©2023 The Korean Nutrition Society and the Korean Society of Community Nutrition This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https:// creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

## ORCID iDs

Özlem Özpak Akkuş D https://orcid.org/0000-0002-1471-8000 Uğurcan Metin D https://orcid.org/0000-0003-3618-684X Zeynep Çamlık D https://orcid.org/0000-0002-0730-5734

#### Funding

This study was financially supported by the Toros University (Project No. 2021-SBF-ÖÖA-1) as a research grant with no role in the design, analysis or writing of this article. The effects of pomegranate peel added bread on anthropometric measurements, metabolic and oxidative parameters in individuals with type 2 diabetes: a double-blind, randomized, placebo-controlled study

## Özlem Özpak Akkuş 向 1§, Uğurcan Metin 🍺 ², and Zeynep Çamlık 🌔 ³

<sup>1</sup>Department of Nutrition and Dietetics, Toros University, Mersin 33140, Turkey <sup>2</sup>Department of Culinary, Toros University, Mersin 33140, Turkey <sup>3</sup>Department of Nutrition and Dietetic, City Hospital, Mersin 33330, Turkey

# ABSTRACT

**BACKGROUND/OBJECTIVES:** The aim of this study was to evaluate the sensory properties of antioxidant-rich bread made by adding pomegranate peels and their effects on anthropometric measurements and metabolic and oxidative parameters of individuals with type 2 diabetes after consumption.

**SUBJECTS/METHODS:** This randomized, double-blind, placebo-controlled study was conducted with 22 individuals aged between 19 and 64 years who had been diagnosed with type 2 diabetes for at least 5 years, used only metformin, did not lose more than 10% of their body weight in the last 6 months, and had a body mass index of  $\geq 25.0$  kg/m<sup>2</sup>. While the study group (n = 11) consumed bread containing 500 mg pomegranate peel daily for 8 wk, the control group (n = 11) consumed standard bread. Anthropometric measurements and metabolic and oxidative parameters of individuals were evaluated at the beginning and end of the study.

**RESULTS:** Decreases were detected in the waist circumference, waist/hip and waist/height ratios, body fat percentages, blood pressure, and serum insulin, triglyceride, and total cholesterol levels in the individuals in the treatment group, compared with those in the control group (P < 0.05).

**CONCLUSIONS:** Pomegranate peel consumption by individuals with type 2 diabetes may have positive effects on anthropometric measurements and glycemic and lipid parameters.

Keywords: Type 2 diabetes mellitus; obesity; pomegranate; antioxidants; lipid peroxidation

# **INTRODUCTION**

Type 2 diabetes is a serious public health problem with a high prevalence. According to a 2017 report published by the International Diabetes Federation, the number of individuals with type 2 diabetes aged 20–79 years may increase from 425 million individuals in 2017 to 629 million by 2045 [1]. This disease, the prevalence of which is ever-increasing, is managed



#### **Conflict of Interest**

The authors declare no potential conflicts of interests.

#### **Author Contributions**

Conceptualization: Özpak Akkuş Ö, Metin U, Çamlık Z; Data curation: Özpak Akkuş Ö, Metin U, Çamlık Z; Formal analysis: Özpak Akkuş Ö, Metin U; Investigation: Özpak Akkuş Ö, Metin U, Çamlık Z; Methodology: Özpak Akkuş Ö, Metin U, Çamlık Z; Project administration: Özpak Akkuş Ö; Resources: Özpak Akkuş Ö, Metin U, Çamlık Z; Validation: Özpak Akkuş Ö, Metin U, Çamlık Z; Visualization: Özpak Akkuş Ö; Writing - original draft: Özpak Akkuş Ö; Writing - review & editing: Metin U, Çamlık Z. by individual or combined approaches such as antidiabetic drug or insulin therapy, medical nutrition therapy, and increased physical activity [2].

Type 2 diabetes and its precursor, insulin resistance, are also associated with obesity, which is another serious public health problem [3]. Obesity is generally evaluated using body mass index (BMI). Central obesity, defined as the accumulation of body fat around the abdominal region, which causes an increase in waist circumference, may also increase the risk of developing type 2 diabetes [4]. A study demonstrated that insulin resistance in women with an increase in BMI over time was related to central obesity and not general obesity [5]. Type 2 diabetes is also associated with dyslipidemia, which is characterized by increased triglyceride (TG) and low-density lipoprotein (LDL) cholesterol levels and decreased high-density lipoprotein (HDL) cholesterol levels, leading to an increased risk of cardiovascular complications [6].

Hyperglycemia, which is one of the most important markers of type 2 diabetes, promotes the production of reactive oxygen species (ROS), thereby inducing oxidative stress and inflammation, which are associated with the production of high-adhesion molecules and proinflammatory cytokines. Therefore, type 2 diabetes, as well as the associated obesity and dyslipidemia, result in cells being easily damaged and a chronic proinflammatory condition that reduces antioxidative potential [7].

In recent years, due to the increasing prevalence of type 2 diabetes and obesity, awareness regarding healthy nutrition, and desire to maintain a healthy life, among other reasons, consumers want to include functional foods that offer health and nutritional benefits in their diets. The functional properties of these foods stem from the presence of phenolic compounds, dietary fibers, oligosaccharides, pro- and pre-biotics, plant sterols, and other nitrogen-containing compounds [8].

Studies have suggested that some dietary polyphenols with a high antioxidant content, especially those found in fruits, have antidiabetic properties because they improve glucose and lipid metabolism in individuals with type 2 diabetes and may be an alternative means of reducing oxidative stress to prevent and manage this disease [9]. Pomegranate, which is one such fruit, also has a high concentration of antioxidants owing to its high phenolic compound content, especially flavonoids and hydrolyzable tannins [10]. The inedible part of the pomegranate fruit, such as the peel, comprises 40% of its total mass and is generally considered waste [11,12]. Similar to the edible part of the fruit, the pomegranate peel has been demonstrated to have a high antioxidant capacity and fiber level because it contains flavonoids and many phenolic compounds [12,13]. Experimental and clinical studies have shown that the pomegranate peel has beneficial effects on blood pressure, glucose, and lipid profiles in patients with type 2 diabetes [2,9,12,14]. Foods made with pomegranate peels and products are considered functional foods that can be implemented in the diets of patients with inflammation-related obesity, type 2 diabetes, and complications such as cardiovascular diseases owing to the phenolic compounds they contain [15].

Although the use of the pomegranate peel is uncommon in the food industry, especially in heat-treated products, studies have shown that it is used in meat products and bread making [15,16]. However, no studies have examined the effect of consuming products produced with pomegranate peels on biochemical parameters. We believe that by determining the effects of products produced with pomegranate peels on glucose and lipid levels, antioxidant



parameters, and anthropometric measurements, these products can be included in the nutritional treatment of type 2 diabetes, cardiovascular diseases, and obesity. Therefore, this study aimed to evaluate the effects of the pomegranate peel and its high antioxidant and fiber content on anthropometric measurements and metabolic and oxidative parameters of individuals with type 2 diabetes who consumed bread produced with antioxidant- and fiber-rich pomegranate peels. We chose bread as it has an important role in daily consumption.

## **SUBJECTS AND METHODS**

## Study design

This randomized, double-blind, parallel-controlled experimental study was carried out between March and April 2022 with 22 individuals aged between 19 and 64 years who were diagnosed with type 2 diabetes at the City Hospital for at least 5 years. Other inclusion criteria were the use of only metformin,  $\leq 10\%$  of body weight loss in the last 6 months, and BMI  $\geq$ 25.0 kg/m<sup>2</sup>. The exclusion criteria were individuals 1) with kidney, liver, and inflammatory diseases; 2) receiving insulin therapy and sulfonylurea; 3) using prescription drugs and/or fiber supplements; 4) using vitamin and mineral supplements; 5) who were pregnant and lactating; 6) consuming excessive alcohol (> 2 drinks/day); 7) with gluten enteropathy; 8) who had an allergic reaction to pomegranates; and 9) who were menstruating. The study participants were matched in terms of sex, age, BMI, and diabetes duration.

For this study, approval was obtained from the Toros University Clinical Research Ethics Committee on June 9, 2021 (number: 2021/425), and written informed consent was obtained from all participants before the study. This study was registered at ClinicalTrials. gov (NCT05232305). For determining the sample size, a power analysis was performed with G\*Power software using alpha ( $\alpha$ ) = 0.05, power (1 –  $\beta$ ) = 0.98, and d = 0.50 (medium effect size), which indicated that at least 10 individuals were required per group. Against any potential problems with the sample (e.g., withdrawals and irregular participation), the study started with 26 volunteers, of whom 4 withdrew at their own request in the following weeks. Subsequently, a researcher randomly assigned individuals to study and control groups using the R programming language. In addition, owing to the double-blind nature of the study, the type of bread consumed by each participant was unknown, and the bread types were only known by their codes to the researchers who produced and distributed the bread in the clinical environment.

## **Dietary intervention**

The study group (n = 11) consumed 500-mg pomegranate peel–added bread (PPB) daily for 8 wk, whereas the control group (n = 11) consumed standard bread (SB) that matched the PPB in shape and size for the same period (**Fig. 1**). We emphasized that the participants must not change their nutritional habits, physical activities, and drug treatments or use any nutritional supplements during the study period. Each participant was provided two slices of bread corresponding with the nutrition program prepared by the researchers who contacted the participants weekly to check whether they consumed the bread during the study.

A questionnaire was administered to the participants in the form of a face-to-face interview, and their general characteristics, anthropometric measurements, and nutritional habits were determined. Blood samples were taken for obtaining biochemical parameters both at the beginning and end of the study. Additionally, a standard nutrition program (not exceeding





Fig. 1. Consort 2010 flow diagram.

60% carbohydrates, 20% proteins, and 30% fats) was prepared for the participants to start at least 1 wk before the study, and 3-day food records were obtained.

### Production and contents of the bread

The pomegranate peelings obtained from a local company (Atışeri, Mersin, Turkey) were separated from the edible part and the red hard outermost part of the fruit and dried at 55°C in the Toros University Food Chemistry Laboratory. They were then ground using a grinder and stored in sealed plastic bags at –18°C until use. The SB and PPB used in the study were produced in the Nutritional Principles Laboratory of the Toros University. For 50 g of SB, 900 mL of water, 42 g of fresh yeast, 12 g of salt, and 12 g of sunflower oil were added to 1,000 g of sifted whole wheat flour, which was then divided into 40 equal parts. For 50 g of PPB, 20 g of pomegranate peel, 914 mL of water, 42 g of wet yeast, 12 g of salt, and 12 g of sunflower oil were added to 1,000 g of whole wheat flour, which was then divided into 40 equal parts (500 mg of pomegranate peel per piece). After the bread doughs were shaped, they were left to rest for 10 min and fermented for 30 min in an incubator at a temperature of 35°C and relative humidity of 85%. Subsequently, the doughs were baked at 180°C for 50 min. **Table 1** shows the amounts of antioxidants and phenolic compounds and nutritional content in the produced breads (50 g).

When the nutrient content in the breads was examined, the macronutrients were in similar proportions, except for fats (**Table 1**). This difference in fat content between the SB and PPB

Nutritional elements	Standard bread	Pomegranate peel-added bread	Pomegranate peel
Energy (kcal)	$143.3 \pm 20$	$138.3 \pm 25$	
CHO (g)	$20.3 \pm 0.2$	$21.9 \pm 0.1$	
Protein (g)	$7.2\pm0.9$	$7.7 \pm 0.1$	
Fat (g)	$3.7 \pm 0.3$	$1.1 \pm 0.1$	
-iber (g)	$2.8 \pm 0.1$	$4.2 \pm 0.1$	
Moisture (g)	$18.0\pm0.2$	$18.5 \pm 0.2$	
Ash (g)	$0.8 \pm 0.1$	$0.8 \pm 0.1$	
FPC (mg gallic acid/g)	$0.4 \pm 0.1$	$0.7 \pm 0.1$	$2.2 \pm 0.2$
DPPH (µmol trolox/g)	$0.8 \pm 0.1$	$2.3 \pm 0.1$	9.5 ± 0.9
ABTS (µmol trolox/g)	$1.5 \pm 0.1$	$4.5 \pm 0.1$	$8.6 \pm 2.1$

Table 1. Quantity and nutritional values of breads (50 g)

All results are given as the mean of three repetitions. Data are presented as mean  $\pm$  SD.

CHO, Carbohydrate; TPC, total phenolic compound; DPPH, 1,1-diphenyl 2-pycrylhydrazyl; ABTS, 2,2-azinobis 3-ethylbenzothiazolin-6-sulfonic acid.

might be because fats that formed a potent complex with the large amounts of polyphenols and flavonoids in the pomegranate peel might have been partially extracted by the solvent [17].

In the study, the amount of pomegranate peel added to the SB recipe for preparing PPB was in accordance with the literature and did not exceed the recommended daily consumption amount of 2.5–4.5 g [2,9,15-18].

## **Documentation of food intake**

For calculating the amount of energy consumed by the individuals during the study period and determining whether there were any changes during the study that might affect the results, the 3-day food consumption of the individuals (2 weekdays and 1 weekend day) was recorded under the supervision of the researcher at the beginning and end of the study. While recording food consumption, the amount of food consumed was calculated using the "Food and Food Photo Catalog—Measurements and Quantities" catalog [19], and the "Standard Meal Recipes" book was used to calculate the portion sizes of meals consumed when eating out and the nutrients included in one portion [20]. With the food consumption records, the total amounts of energy, macronutrients, fiber, and cholesterol consumed were calculated using the Nutrition Information System (BeBIS) 8.2 software package [21].

## **Evaluation of anthropometric measurements**

Body weight, height, waist circumference, hip circumference, and body composition measurements of the participants were obtained in the face-to-face interviews conducted by the researcher both at the beginning and end of the study, and BMI and the waist-hip ratio of the individuals were calculated using this information.

## Height measurement

Height was measured by fixing an infrared height meter scale to the wall, with the feet side by side and head in the Frankfort plane (the eye triangle and top of the auricle are aligned) [22].

## Body weight measurement

Body weight of the individuals was measured with minimum clothing and no shoes with a portable digital indicator sensitive to 0.1 kg on the infrared height meter scale [22].

### BMI calculation

BMI was used to evaluate both malnutrition and obesity and was calculated by dividing weight (kg) by height  $(m^2)$  (kg/m<sup>2</sup>) [22].



#### Waist and hip circumference measurements

Waist circumference was measured from the midpoint of the lower rib and crista iliaca, and hip circumference was measured using a measuring tape at the widest part of the hip. Waist/ hip and waist/height ratios were calculated using these measurements [23].

### Body composition

Body measurements (body fat, lean mass, and water amount and percentages) were taken with body composition analyzer (Tanita BC-418, Tanita Corporation, Tokyo, Japan) after implementing measurement conditions such as not performing heavy physical activity 24 h before the analysis, not consuming alcohol, eating food and drinking water at least 2 h before the analysis, and not drinking tea, coffee, and acidic beverages at least 4 h before the analysis [22].

#### Blood pressure measurements

In the sitting position, blood pressure was measured using a digital blood pressure device (OMRON IntelliSense, HEM-907XL; OMRON Healthcare, Kyoto, Japan) with an accuracy of  $\pm$  5 mmHg in the right arm. Three consecutive measurements were taken at 5-min intervals, and the mean values were calculated.

#### Evaluation of biochemical parameters

At the beginning and end of the study, basal blood samples were taken from the participants at the City Hospital Biochemistry Laboratory after 8–12 h of fasting. Fasting blood glucose (FBG), fasting insulin, glycated hemoglobin (HbA1c), total cholesterol, TG, LDL cholesterol, and HDL cholesterol levels, total antioxidant capacity (TAC), and thiobarbituric acid reactive substance (TBARS) values were measured from the blood samples.

Biochemical parameters were analyzed at the City Hospital Biochemistry Laboratory and assessed on the basis of the laboratory's standards. FBG was measured with ultraviolet test analysis, HbA1c with the immunoinhibition method, insulin with the chemical immunoassay, total cholesterol with the cholesterol oxidase method, TG with the glycerol phosphate oxidase method, and HDL cholesterol with the enzymatic colorimetric method. LDL cholesterol levels were calculated using the Friedewald equation (LDL cholesterol = total cholesterol – HDL cholesterol - (TG/5)). Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) values were calculated with the following formula: FBG (mg/dL) × fasting insulin (IU/mL)/405, and HOMA-IR  $\ge$  2.5 was defined as insulin resistance. TAC was measured with the spectrophotometric method (Mindray BS-300), and TBARS was measured with the enzyme-linked immunosorbent assay method (BioTek 800 TS) with commercial kits (Rel Assay Diagnostics, Ankara, Turkey).

#### **Sensory analyses**

Sensory analyses of the bread samples were performed within 24 h after the breads were removed from the oven. Crust and inner colors, flavor, odor, hardness, pore structure, chewability, and general taste of the breads were evaluated by 20 trained panelists using a 5-point Likert scale (5 = liked it; 4 = liked it somewhat; 3 = neither liked nor disliked it; 2 = slightly disliked it; and 1 = disliked it).

#### Statistical evaluation of the data

Frequency analyses and mean comparison tests were performed. During the first stage, frequency analyses of the demographic characteristics and nutritional habits of the individuals were performed, and the frequencies (n) and percentages (%) of the groups



were presented together. During the second stage, the results of inter-group and intragroup comparisons of dietary energy, nutrient intake, anthropometric measurements, and metabolic and oxidative stress parameters of individuals based on bread types were presented at beginning and after 8 wk of intervention. The Shapiro–Wilk normality test and Levene's variance homogeneity test results were analyzed to select the most appropriate hypothesis tests. As appropriate hypothesis tests for normally distributed measurements, an independent samples t-test was used for the independent group comparisons, and a paired t-test was used for two dependent group comparisons. The hypothesis tests were conducted together, obtaining the mean difference and the lower and upper limit values of the confidence intervals of the differences. All analyses were performed using SPSS version 26 (IBM; Armonk, NY, USA) and the margin of error was set at < 0.05.

## RESULTS

All 22 participants completed the study and were included in the analysis. We found no statistically significant differences between participants in both groups in terms of sex (PPB n = 11; 6 female individuals; SB n = 11; 5 female individuals), or age and diabetes duration (PPB 54.1  $\pm$  10.6 yrs, 73.1  $\pm$  8.4 mon; SB 54.5  $\pm$  9.7 yrs, 74.7  $\pm$  11.2 mon, respectively) (*P* > 0.05). In addition, we found no statistically significant between-group differences in terms of dietary intake (**Table 2**), anthropometric characteristics (**Table 3**), and biochemical markers (**Table 4**) at the beginning of the study (*P* > 0.05).

## **Results of the sensory analyses**

**Table 5** shows the results of the sensory analyses of the breads used in the study. The participants liked the PPB more than the SB in terms of all the evaluated sensory parameters, but only the sensory parameters of flavor, odor, chewability, and pore structure showed statistically significant differences (P < 0.05).

## **Results of energy and nutrient intake measurements**

Dietary total energy values and nutrient intake amounts of PPB- and SB-consuming individuals calculated at the beginning and after 8 wk of the intervention are shown in **Table 2**. On evaluating both intra-group and inter-group comparison results of the groups consuming PPB and SB, we observed that the differences were not statistically significant (P > 0.05).

#### **Results of anthropometric measurements**

The anthropometric measurements of individuals with type 2 diabetes who consumed SB and PPB are shown in **Table 3**. On evaluating the intra-group comparison results, we determined that the waist circumference, hip circumference, waist/hip ratio, waist/height ratio, body fat percentage, systolic blood pressure (SBP), and diastolic blood pressure (DBP) of the individuals who consumed PPB were higher at the beginning of the study than after 8 wk of the intervention, whereas the fat-free mass percentage was lower; these differences were statistically significant (P < 0.05). In addition, the hip circumference was significantly higher at the beginning of the study than after 8 wk of the intervention in the SB group (P < 0.05). On examining the inter-group comparison results of the changes observed in each group, we observed that the changes in SBP and DBP measured after 8 wk of the intervention in individuals who consumed PPB were significantly higher than those measured in individuals who consumed SB (P < 0.05), whereas the other anthropometric measurements did not show statistically significant differences according to the bread type (P > 0.05) (**Table 3**).



Table 2. Dietary total energy values and nutrient intake amounts of PPB- and SB-consuming individuals calculated at the beginning and after 8 wk of the intervention

Variables	Gro	95% CI	P value <sup>1)</sup>	
	PPB (n = 11)	SB (n = 11)		
Total energy (kcal) Beginning After 8 wk Change 95% Cl <i>P</i> value <sup>2)</sup>	$\begin{array}{c} 1,417.20\pm511.12\\ 1,311.84\pm534.10\\ 105.36\pm256.50\\ 105.36\ (-75.37\ to\ 286.09)\\ 0.223\end{array}$	$\begin{array}{c} 1,233.68 \pm 250.41 \\ 1,300.24 \pm 350.73 \\ -66.56 \pm 226.96 \\ -66.56 \left(-226.48 \text{ to } 93.36\right) \\ 0.376 \end{array}$	183.52 (–174.45 to 541.5) 11.60 (–390.27 to 413.47) 171.92 (–54.01 to 397.85)	0.298 0.953 0.128
Protein (g) Beginning After 8 wk Change 95% Cl <i>P</i> value <sup>2)</sup>	$62.28 \pm 20.37$ $60.00 \pm 25.18$ $2.28 \pm 16.02$ 2.28 (-9.01  to  13.57) 0.663	$51.45 \pm 13.22$ $56.73 \pm 16.41$ $-5.28 \pm 14.45$ 5.28 (-15.46  to  4.90) 0.275	10.83 (-4.44 to 26.1) 3.27 (-15.63 to 22.17) 7.56 (-6.67 to 21.79)	0.155 0.722 0.281
Fat (g) Beginning After 8 wk Change 95% Cl <i>P</i> value <sup>2)</sup>	$65.09 \pm 29.80$ $58.0 \pm 26.11$ $7.08 \pm 17.02$ 7.08 (-4.91  to  19.07) 0.218	$67.61 \pm 16.93$ $71.51 \pm 27.49$ $-3.89 \pm 21.94$ 3.89 (-19.35 to 11.57) 0.587	2.53 (-24.08 to 19.03) 13.50 (-37.34 to 10.34) 10.98 (-7.34 to 29.29)	0.809 0.251 0.226
CHO (g) Beginning After 8 wk Change 95% Cl P value <sup>2)</sup>	$141.99 \pm 53.35$ $134.17 \pm 54.76$ $7.82 \pm 32.26$ $7.82 (-14.91 \text{ to } 30.55)$ $0.461$	$102.11 \pm 27.14$ $105.41 \pm 38.7$ $-3.30 \pm 25.15$ $3.3 (-21.02 \text{ to } 14.42)$ $0.687$	39.89 (2.24 to 77.54) 28.77 (–14.41 to 70.94) 11.12 (–15.86 to 38.11)	0.139 0.170 0.400
Fiber (g) Beginning After 8 wk Change 95% CI P value <sup>2)</sup>	$21.45 \pm 9.08$ $23.23 \pm 12.35$ $-1.78 \pm 10.88$ -1.78 (-9.44  to  5.89) 0.617	$18.73 \pm 9.28$ 20.44 \pm 10.86 -1.71 \pm 7.07 -1.71 (-6.69 to 3.28) 0.463	2.72 (-5.44 to 10.89) 2.79 (-7.55 to 13.13) -0.07 (-8.63 to 8.49)	0.495 0.580 0.987
Cholesterol (mg) Beginning After 8 wk Change 95% Cl P value <sup>2)</sup>	$\begin{array}{c} 313.02 \pm 145.92 \\ 260.60 \pm 155.30 \\ 52.42 \pm 165.87 \\ 52.42 \left(-64.45 \text{ to } 169.29\right) \\ 0.341 \end{array}$	$\begin{array}{c} 282.23 \pm 111.96 \\ 279.10 \pm 109.27 \\ 3.13 \pm 165.43 \\ 3.13 \left(-113.43 \ \text{to} \ 119.69\right) \\ 0.953 \end{array}$	30.79 (-84.89 to 146.47) -18.50 (-137.93 to 100.93) 49.29 (-105.24 to 203.81)	0.585 0.750 0.513
Vit A (µg) Beginning After 8 wk Change 95% Cl <i>P</i> value <sup>2)</sup>	$1,090.42 \pm 738.69$ $1,319.98 \pm 999.60$ $-229.56 \pm 803.95$ $-229.56 (-796.02 \text{ to } 336.91)$ $0.388$	$\begin{array}{c} 1,597.42 \pm 1,413.90 \\ 1,301.58 \pm 1,030.73 \\ 295.84 \pm 1,555.29 \\ 295.84 \left(-800.02 \ \text{to} \ 1,391.70\right) \\ 0.561 \end{array}$	-507.00 (-1,510.31 to 496.31) 18.40 (-884.66 to 921.45) -525.39 (-1,680.29 to 629.50)	0.304 0.967 0.354
Vitamin E (mg) Beginning After 8 wk Change 95% CI <i>P</i> value <sup>2)</sup>	$24.54 \pm 19.10$ $23.35 \pm 12.15$ $1.19 \pm 10.74$ 1.19 (-6.38  to  8.76) 0.734	$23.53 \pm 9.96$ $28.80 \pm 15.46$ $-5.27 \pm 12.64$ -5.27 (-14.18  to  3.63) 0.216	1.01 (-12.54 to 14.56) -5.45 (-17.82 to 6.91) 6.46 (-4.48 to 17.41)	0.878 0.369 0.232
Vitamin C (mg) Beginning After 8 wk Change 95% Cl <i>P</i> value <sup>2)</sup>	$159.4 \pm 79.52$ $142.55 \pm 78.44$ $16.84 \pm 56.02$ 16.84 (-22.62  to  56.31) 0.364	$138.87 \pm 116.03$ $130.81 \pm 124.62$ $8.06 \pm 65.68$ $8.06 (-38.22 \text{ to } 54.34)$ $0.706$	20.53 (-67.94 to 109.00) 11.74 (-80.87 to 104.35) 8.78 (-48.16 to 65.73)	0.634 0.794 0.751
Selenium (mg) Beginning After 8 wk Change 95% Cl P value <sup>2)</sup>	$13.52 \pm 9.27$ $11.74 \pm 7.54$ $1.79 \pm 7.89$ $1.79 (-3.77 \text{ to } 7.35)$ $0.491$	$12.86 \pm 8.55$ $10.65 \pm 7.94$ $2.21 \pm 12.19$ $2.21 (-6.38 to 10.80)$ $0.579$	0.66 (-7.27 to 8.59) 1.09 (-5.80 to 7.97) -0.42 (-10.00 to 9.16)	0.863 0.746 0.928

Data are presented as mean  $\pm$  SD.

PPB, pomegranate peel-added bread consumers; SB, standard bread consumers; CI, confidence interval.

<sup>1)</sup>Independent samples *t*-test; <sup>2)</sup>Paired *t*-test.



Table 3. The anthropometric measurements of PPB- and SB-consuming individuals measured calculated at the beginning and after 8 wk of the intervention

PP8 (n-13)         58 (n-13)           Beginning         B8.27 : 1.8.2         B7.01 : 12.34         1.23 (-12.91 to 15.4)         0.856           After 8 vk         B6.85 : 1.8.35         B8.77 : 11.16         1.06 (-12.43 to 15.4)         0.856           Otange         1.42 - 2.31         1.25 - 1.67         0.16 (1.20 to 2.12)         0.864           95% C1         1.42 (-2.11 to 3.04)         0.064 to 2.57         0.16 (1.20 to 2.12)         0.864           95% C1         0.061 to 2.57         0.061 to 2.57         0.01 (-0.61 to 0.87)         0.73 (-4.79 to 5.34)         0.73 (-5.75 to 5.75 to	Variables	Grou	ips	95% CI	P value <sup>1)</sup>	
Body weight (kg)         U <thu< th=""> <thu< th=""> <thu< th="">         &lt;</thu<></thu<></thu<>		PPB (n = 11)	SB (n = 11)	-		
Beginning         68.27 : 1.8.2         97.03 : 12.34         1.25 (-1.25 to 15.4)         0.856           After 8 wk         66.85 : 1.8.35         85.7 : 11.16         0.16 (-1.40 to 2.12)         0.864           S5% (1)         1.42 : 2.31         1.25 : 1.87         0.36 (-1.40 to 2.12)         0.864           Bigning         9.066 : 4.40         0.06         0.06         0.73 (-4.79 to 3.34)         0.713           Mart 8 wk         9.051 : 54.40         2.09 ± 4.04         -0.84 (-4.59 to 3.34)         0.754           Bigning         0.52 : 0.91         0.41 : 0.60         0.11 (-0.51 to 0.31)         0.754           Bisk (1)         0.52 (-0.12 to 1.16)         0.41 (-0.01 to 0.38)         0.754           Bisk (1)         0.52 (-0.12 to 1.16)         0.41 (-0.51 to 0.34)         0.754           Bisk (1)         0.50 : 12.67         97.00 - 8.44         -0.06 (-1.72 to 7.72)         0.572           Ohange         3.82 (1.74 to 5.59)         2.64 (-2.71 to 1.36 to 3.82)         0.64 (-2.51 to 0.38)         0.757           Wata chromifermore (cm)         U         0.002 *         0.012         0.86 (-3.57 to 0.56)         0.92 (-0.57 to 0.56)         0.931           After 8 wk         1.02.57 to 0.60 (-0.57 to 0.56)         0.021 (-0.57 to 0.56)         0.312         0.46	Body weight (kg)					
After 8 wk         66.85 : 11.35         85.77 : 11.16         1.06 (-1.24 to 1.45)         0.868           Change         1.42 : 2.31         1.25 : 1.167         0.16 (-1.20 to 2.12)         0.864           Pvalue <sup>1</sup> 0.081         0.061         0.061         0.061           Beginning         29.66 : 4.80         30.39 : 4.33         -0.73 (-4.79 to 3.34)         0.713           After 8 wk         20.15 : 4.40         20.39 : 4.04         -0.24 (-3.91 to 2.32)         0.647           Change         0.52 : 0.01         0.41 (-0.01 to 0.83)         0.713         0.737           Pvalue <sup>2</sup> 0.52 : 0.01 : 0.47         97.01 : 8.44         -0.32 (-1.17 to 7.4)         0.869           After 8 wk         35.00 : 12.67         97.00 : 8.44         -0.02 (-1.17 to 7.7)         0.672           Change         3.82 : 2.05         2.64 - 2.71         1.18 (-1.46 to 3.82)         0.382           93% C1         3.82 : 2.05         2.64 - 2.71         1.18 (-1.46 to 3.82)         0.382           93% C1         1.73 : 2.05         2.46 (-2.03 to 4.34)         0.377 (-7.07 to 7.6)         0.931           948 c1         1.73 : 2.05         0.35 : -0.06         -0.02 (-0.01 to 0.06)         0.822           95% C1         1.73 : 2.06         0.35	Beginning	$88.27 \pm 18.82$	$87.03 \pm 12.34$	1.25 (-12.91 to 15.4)	0.856	
Change         1.42 ± 2.13         1.25 ± 1.67         0.56 (-1.60 to 2.19)         0.684           95% C1         0.061         0.065         0.065         0.065           Positile*         0.061         0.052         0.051         0.052         <	After 8 wk	$86.85 \pm 18.35$	$85.77 \pm 11.16$	1.08 (-12.43 to 14.59)	0.869	
9 5% C1 1.42 (-0.21 to 3.03) 1.25 (-0.06 to 2.57) Pvalue <sup>9</sup> 0.061 0.06 BM (gym <sup>2</sup> ) Beginning 2.35.5 + 4.40 2.9.8 + 4.04 -0.84 (-4.51 to 2.92) 0.647 Change 0.52 + 0.51 0.41 + 0.66 -0.81 (-4.51 to 2.92) 0.647 S% C1 0.52 (-5.12 to 1.16) 0.41 (-0.01 to 0.03) 0.754 Beginning 98.82 + 13.09 98.64 + 9.62 -0.82 (-11.03 to 9.4) 0.869 Alter 8 vk 3.50 - 12.67 97.00 + 8.44 -2.00 (-11.72 to 7.72) 0.672 S% C1 3.52 (-2.14 to 5.50) 2.64 + 2.72 1.18 (-1.41 to 0.82) Pvalue <sup>9</sup> 0.002 0.112 Hip circumference (cm) Beginning 98.82 + 13.09 98.64 + 9.62 -0.82 (-11.03 to 9.4) 0.869 Alter 8 vk 3.50 - 12.67 97.00 + 8.44 -2.00 (-11.72 to 7.72) 0.672 S% C1 3.52 (-2.14 to 5.50) 2.64 (0.73 to 4.54) 0.002 0.112 Hip circumference (cm) Beginning 0.04 0.9 ± 9.31 104.55 ± 9.82 -0.46 (-9.02 to 8.09) 0.9311 After 8 vk 102.58 2.86 100.02 ± 6.03 0.07 (-1.07 to 7.63) 0.339 Change 0.02 (-0.01 to 0.94 ± 9.32) 0.12 +0.14 to 0.320 Change 0.024 (0.14 to 0.34) Pvalue <sup>9</sup> 0.002 <sup>1</sup> 0.112 Fwalue <sup>8</sup> 0.044 0.015 Waist/hip ratio Beginning 0.04 + 0.08 0.55 -0.07 -0.01 (0.07 to 0.06) 0.822 After 8 vk 0.02 (-0.01 to 0.09 0.000 -0.03 0.02 (-0.01 to 0.09 0.339 95% C1 0.024 (0.01 to 0.0) 0.00 (-0.02 to 0.02) 0.02 (-0.01 to 0.04) 0.339 95% C1 0.024 (0.01 to 0.03) 0.02 (-0.01 to 0.04) 0.339 Pvalue <sup>9</sup> 0.002 <sup>1</sup> 0.032 Pvalue <sup>9</sup> 0.002 <sup>1</sup> 0.033 Change 0.024 0.01 to 0.03 0.02 (-0.01 to 0.04) 0.354 Change 0.024 (0.01 to 0.03) 0.01 (-0.01 to 0.02) 0.427 Pystule <sup>9</sup> 0.007 <sup>1</sup> 0.112 Beginning 0.55 -0.06 0.58 -0.06 -0.002 (-0.07 to 0.04) 0.554 Change 0.024 (0.01 to 0.03) 0.01 (-0.01 to 0.02) 0.427 Pystule <sup>9</sup> 0.027 <sup>1</sup> 0.112 Beginning 0.55 -0.06 0.58 -0.06 -0.002 (-0.07 to 0.04) 0.554 Change 0.024 (0.01 to 0.03) 0.01 (-0.01 to 0.02) 0.427 Pystule <sup>9</sup> 0.027 <sup>1</sup> 0.121 Beginning 6.35 -2.068 0.58 -0.06 -0.002 (-0.07 to 0.04) 0.554 Change 0.024 (0.01 to 0.03) 0.01 (-0.01 to 0.02) 0.427 Pystule <sup>9</sup> 0.027 <sup>1</sup> 0.439 Beginning 6.35 -5.68 6.53 7 -6.59 1.57 -5.75 6.75 8.7 3.50 0.537 Change 0.024 (-0.01 to 0.03) 0.024 (-0.01 to 0.02) 0.427 Pystule <sup>9</sup> 0.027 <sup>1</sup> 0.	Change	$1.42 \pm 2.31$	$1.25 \pm 1.87$	0.16 (-1.80 to 2.12)	0.864	
P Aule <sup>19</sup> 0.061         0.06           Big(Ing/m)         29.66 : 4.80         33.39 : 4.33         -0.73 (.4.79 to 3.34)         0.713           After 8 wk         29.31.5 : 4.40         29.89 : 4.04         -0.84 (.4.59 to 2.34)         0.754           Syste, C1         0.52 (-0.12 to 1.16)         0.41 (-0.61 to 0.33)         0.754           Syste, C1         0.52 (-0.12 to 1.16)         0.41 (-0.61 to 0.32)         0.754           Waits clearmbernee (cm)         Beginning         98.82 + 13.09         99.84 + 9.62         -0.82 (-11.03 to 9.4)         0.869           Syste, C1         38.50 a 11.567         97.00 to 8.44         -2.00 (-1.12 to 7.72)         0.672           Change         3.82 ± 2.25         2.64 ± 2.11         1.13 (-1.46 to 3.89)         0.362           Syste, C1         3.02 × 4.8.46         10.09 × 8.03         0.27 (-7.07 to 7.61)         0.312           P value <sup>3</sup> 0.024         0.012         0.391         0.455 ± 9.92         -0.045 (-5.92 to 8.09)         0.931           Syste, C1         1.73 ± 2.05         2.46 ± 2.66         -0.74 (-2.95 to 1.49)         0.486           Syste, C1         0.024 (0.00 to 0.03)         0.02 (-0.07 to 0.06)         0.822         0.06           Syste, C1         0.024 (0.00 to 0.03)<	95% CI	1.42 (-0.21 to 3.05)	1.25 (-0.06 to 2.57)			
BNI (By/m <sup>2</sup> ) Beginning 29.65 - 4.80 30.39 - 4.31 -0.73 (-4.79 to 3.34) 0.713 After 9 wk 20.15 - 4.40 29.98 - 4.04 -0.84 (-4.59 to 2.92) 0.647 Change 0.524 .031 0.41 -0.60 -0.84 -0.84 (-4.59 to 2.92) 0.647 95% Cl 0.52 (-0.12 to 1.16) 0.41 (-0.01 to 0.83) 0.754 95% Cl 0.052 (-0.12 to 1.16) 0.41 (-0.01 to 0.83) 0.754 Beginning 98.82 + 13.09 99.64 + 9.62 -0.52 (-11.03 to 9.4) 0.669 After 9 wk 95.00 - 12.67 97.00 - 8.84 -27.00 (-11.79 to 7.72) 0.672 Change 3.824 (1.74 to 5.90) 2.64 (0.73 to 4.54) 0.112 Hip circumference (m) Beginning 104.09 - 9.31 104.55 - 9.92 -0.46 (-9.02 to 8.00) 0.911 After 9 wk 102.36 - 8.46 100.09 - 8.30 0.27 (-7.07 to 7.61) 0.939 Change 1.73 - 2.05 2.46 - 2.66 -0.74 (-2.95 to 1.49) 0.496 95% Cl 1.73 (0.28 to 3.17) 2.46 (0.35 to 3.4) 0.015' Waist/Ip ratio Beginning 0.04 + 0.08 0.05 - 0.07 -0.01 (-0.07 to 0.06) 0.422 After 9 wk 0.92 + 0.08 0.05 - 0.07 -0.01 (-0.07 to 0.06) 0.422 After 9 wk 0.92 + 0.08 0.05 - 0.06 -0.02 (-0.03 to 0.04) 0.422 Change 0.02 0.00 0.00 0.03 -0.02 (-0.03 to 0.04) 0.422 Change 0.02 0.00 0.03 -0.02 (-0.01 to 0.09) 0.399 95% Cl 0.02 (0.01 to 0.03) 0.00 (-0.02 to 0.02) After 9 wk 0.92 + 0.08 0.55 - 0.06 -0.02 (-0.03 to 0.04) 0.422 After 9 wk 0.92 + 0.08 0.55 - 0.07 -0.01 (-0.07 to 0.06) 0.522 After 9 wk 0.92 + 0.02 0.00 -0.03 0.002 (-0.03 to 0.04) 0.422 Change 0.02 0.00 0.03 0.00 (-0.02 to 0.03) 0.399 95% Cl 0.02 (0.01 to 0.03) 0.00 (-0.02 to 0.02) 0.03 95% Cl 0.02 (0.01 to 0.03) 0.01 (0.00 to 0.03) 95% Cl 0.02 (0.01 to 0.03) 0.01 (0.00 to 0.03) 95% Cl 0.02 (0.01 to 0.03) 0.01 (0.00 to 0.03) 95% Cl 0.02 (0.01 to 0.03) 0.01 (0.00 to 0.03) 95% Cl 0.02 (0.01 to 0.03) 0.01 (0.00 to 0.03) 95% Cl 0.02 (0.01 to 0.03) 0.01 (0.00 to 0.03) 95% Cl 0.02 (0.01 to 0.03) 0.01 (0.00 to 0.03) 95% Cl 0.02 (0.01 to 0.03) 0.01 (0.00 to 0.03) 95% Cl 0.02 (0.01 to 0.03) 0.01 (0.00 to 0.03) 95% Cl 0.02 (0.01 to 0.03) 0.01 (0.00 to 0.03) 95% Cl 0.02 (0.01 to 0.03) 0.01 (0.00 to 0.03) 95% Cl 0.02 (0.01 to 0.03) 0.02 (-0.07 to 0.07 (-0.07 (-0.14) 0.649) 0.554	P value <sup>2)</sup>	0.081	0.06			
Beginning         29.66 + 480         30.39 + 4.33         -0.73 + (79 to 3.34)         0.73           After 8 wik         29.15 + 4.40         29.89 + 4.04         -0.84 (-4.35 to 2.9)         0.647           Change         0.52 - 0.01         0.41 - 0.60         0.11 (-0.61 to 0.83)         0.754           Syste C1         0.02 (-0.12 to 1.16)         0.41 (-0.61 to 0.83)         0.754           Watta Clearmferance (cm)         Beginning         98.82 + 13.09         99.64 + 9.62         -0.62 (-11.03 to 9.4)         0.667           Mater 8 wk         95.00 + 12.67         97.00 + 8.84         -2.00 (-11.27 to 7.2)         0.672           Ohange         3.82 + 2.25         2.64 + 2.71         1.18 (-1.46 to 3.82)         0.382           95% C1         3.73 (0.28 to 3.17)         2.46 (0.73 to 4.54)         0.899           Paula <sup>4</sup> 0.002 <sup>4</sup> 0.112         0.46 (-3.02 to 8.09)         0.931           After 8 wk         102.36 to 8.46         102.09 + 8.03         0.27 (-7.07 to 7.6)         0.899           Change         1.73 to 2.08 0.317         2.46 (0.65 to 4.314)         0.486         9.5 + 0.07         -0.01 (-0.07 to 0.06)         0.822           Watter Numeria         0.024 0.01 0.00         0.02 (-0.007 to 0.04)         0.422         0.016 0.032 <td>BMI (kg/m²)</td> <td></td> <td></td> <td></td> <td></td>	BMI (kg/m²)					
After sik         29.15 ± 4.40         29.38 ± 4.04         -0.41 ± 0.60         0.14 ± 0.60         0.60	Beginning	29.66 ± 4.80	$30.39 \pm 4.33$	-0.73 (-4.79 to 3.34)	0.713	
Change         0.52 (-0.12 to 1.16)         0.41 (-0.60 to 0.30)         0.11 (-0.61 to 0.83)         0.754           P value <sup>21</sup> 0.001         0.056         0.056         0.056         0.056         0.056         0.056         0.056         0.056         0.056         0.056         0.0672         0.0672         0.77         0.77	After 8 wk	$29.15 \pm 4.40$	$29.98 \pm 4.04$	-0.84 (-4.59 to 2.92)	0.647	
SPNC T         0.55 (- 0.12 to 1.16)         0.41 (-0.01 to 0.83)           Waiter formation         0.066           Waiter formation         0.066           Mater structure formation         0.656           Seginning         3.82 ± 1.209         99.64 ± 8.62         -0.82 (-11.03 to 9.4)         0.689           System         3.82 ± 2.85         9.64 ± 2.71         1.18 (-1.46 to 3.82)         0.362           System         3.82 ± 2.85         9.64 ± 2.71         1.18 (-1.46 to 3.82)         0.362           Praduet         0.002"         0.112         Hill         Praduet         0.393         0.393           Praduet         0.002"         0.112         Hill         0.46 (-9.02 to 8.09)         0.911           Beginning         104.09 ± 9.31         104.55 ± 9.92         -0.46 (-9.02 to 8.09)         0.933           Change         1.73 (0.28 to 3.17)         2.46 (0.53 to 4.34)         -0.74 (-2.95 to 1.48)         0.496           System         0.024         0.035         0.02 (-0.07 to 0.06)         0.822         Change         0.02 (-0.07 to 0.04)         0.496           System         0.022 to 0.2         0.00 (-0.02 to 0.02)         0.02 (-0.07 to 0.04)         0.492           System         0.026 (-0.01 to 0.03)         <	Change	$0.52 \pm 0.91$	$0.41 \pm 0.60$	0.11 (-0.61 to 0.83)	0.754	
P value <sup>3</sup> 0.001         0.056           Wais discumentare (cm)         99.44 ± 9.60         -0.82 (-11.03 to 9.4)         0.869           After 8 wik         95.00 ± 12.67         97.00 ± 8.44         -2.00 (-11.72 to 7.72)         0.672           Change         3.82 (1.74 to 5.90)         2.64 (-7.21 to 4.57)         1.18 (-1.64 to 3.82)         0.652           Sys G1         3.82 (1.74 to 5.90)         2.64 (-7.21 to 4.57)         1.18 (-1.64 to 3.82)         0.931           Ip originarisme (cm)         100.23 to 8.46         102.09 to 8.03         0.07 (-7.07 to 7.61)         0.931           After 8 wik         10.73 + 2.05         2.46 (-5.50 to 4.34)         0.45 (-9.00 to 0.69)         0.939           Sys G1         1.73 (0.28 to 3.17)         2.46 (0.55 to 4.34)         0.496         0.496           Sys G1         0.024         0.025         0.02 (-0.00 to 0.69)         0.822           After 8 wik         0.92 = 0.02         0.00 = 0.02 (-0.01 to 0.04)         0.422           After 8 wik         0.92 = 0.02         0.002 (-0.01 to 0.02)         0.22 (-0.01 to 0.4)           Sys C1         0.022 (-0.01 to 0.03)         0.002 (-0.01 to 0.02)         0.422           After 8 wik         0.55 = 0.06         0.51 = 0.06         0.51 = 0.06         0.52 + 0.02 (-0.01	95% CI	0.52 (-0.12 to 1.16)	0.41 (-0.01 to 0.83)	, , , , , , , , , , , , , , , , , , ,		
Waist circumference (cm)         Segments         Segme	<i>P</i> value <sup>2)</sup>	0.101	0.056			
Beginning         98.82 ± 3.09         99.64 ± 9.62         -0.82 (± 11.03 to 9.4)         0.869           After 8 wk         95.00 ± 12.67         97.00 ± 8.44         -2.00 (± 11.03 to 9.4)         0.869           95% C1         3.82 ± 2.95         2.64 ± 2.71         1.18 (± 1.46 to 3.82)         0.362           P value <sup>3</sup> 0.002"         0.112         0.872         0.872           Hip circumfrence (cm)         -	Waist circumference (cm)					
After 8 wk         95.00 ± 12.67         97.00 ± 8.44         -2.00 (± 11.72 to 7.72)         0.672           Change         3.82 ± 25         2.64 ± 7.1         1.18 (-1.46 to 3.82)         0.622           95% Cl         3.82 (1.74 to 5.90)         2.64 (0.73 to 4.54)         0.022         0.112           Hip discurfiement (cm)           0.022         0.112         0.455 ± 9.92         0.46 (-9.02 to 8.09)         0.911           After 8 wk         102.36 ± 8.46         102.09 ± 0.33         0.27 (-7.07 to 7.61)         0.439           S5% Cl         1.773 (2.250 5         2.46 (5.35 to 4.34)         0.496         0.55           Waits/hip rato           0.024'         0.015'         0.77 (-0.01 (-0.07 to 0.06)         0.892           Mare 7 wk         0.92 ± 0.08         0.95 ± 0.07         -0.01 (-0.07 to 0.06)         0.892           Change         0.02 ± 0.02         0.000 ± 0.03         0.02 (-0.07 to 0.06)         0.492           Pvalue <sup>27</sup> 0.020 ± 0.02         0.000 ± 0.03         0.02 (-0.07 to 0.06)         0.492           Change         0.02 ± 0.02         0.01 ± 0.01         0.01 (-0.01 to 0.02)         0.492           Pvalue <sup>27</sup> 0.020 ± 0.02         0.01 ± 0.01         0.01 (-0.01 to 0.02)<	Beginning	$98.82 \pm 13.09$	$99.64 \pm 9.62$	-0.82 (-11.03 to 9.4)	0.869	
$\begin{array}{cccc} {\rm Change} & 3.82 \pm 2.95 & 2.64 \pm 2.71 & 1.18 \left( -1.46 \ {\rm to} \ 3.82 \right) & 0.362 \\ {\rm P value^n} & 0.002^n & 0.112 \\ \\ {\rm Hjc circumference (m)} & & & & & & & & & & & & & & & & & & &$	After 8 wk	$95.00 \pm 12.67$	97.00 ± 8.84	-2.00 (-11.72 to 7.72)	0.672	
sss ci P value <sup>3</sup> 3.2 (1.74 to 5.90) 0.002"         0.112           Hip circumference (cm)         -0.46 (-9.02 to 8.03) 0.37 (-7.07 to 7.61)         0.393 0.393           After 8 wk         102.36 8.46         102.09 8.03         0.27 (-7.07 to 7.61)         0.393 0.493           S5% CI         1.73 ± 0.05         2.46 ± 2.66         -0.74 (-2.95 to 1.48)         0.496           S5% CI         1.73 ± 0.05         2.46 ± 2.66         -0.74 (-2.95 to 1.48)         0.496           S5% CI         0.024"         0.015"         0.422         0.466         0.422           Change         0.024 to 0.02         0.000 ± 0.03         0.02 (-0.01 to 0.04)         0.139           95% CI         0.022 (0.01 to 0.03)         0.000 (-0.02 (0.00 to 0.02)         0.422         0.466           P value <sup>3</sup> 0.000 (-0.02 to 0.02)         0.000 (-0.02 (-0.01 to 0.03)         0.319           95% CI         0.022 (0.01 to 0.03)         0.01 (-0.01 to 0.03)         0.330           Change         0.002 (-0.01 to 0.03)         0.01 (-0.01 to 0.03)         0.390           P value <sup>3</sup> 0.002 (-0.01 to 0.03)         0.310         0.427           P value <sup>3</sup> 0.002 (-0.01 to 0.03)         0.310         0.427           95% CI         0.022 (0.01 to 0.03)	Change	$3.82 \pm 2.95$	$2.64 \pm 2.71$	1.18 (-1.46 to 3.82)	0.362	
P value <sup>3</sup> 0.002 <sup>4</sup> 0.112           Hip circumfrence (cm)	95% CI	3.82 (1.74 to 5.90)	2.64 (0.73 to 4.54)	, , , , , , , , , , , , , , , , , , ,		
Hip circumference (cm)       9         Beginning       104.05 ± 9.92       -0.46 (-9.02 to 8.09)       0.911         After 8 wk       102.36 ± 8.46       102.09 ± 8.03       0.27 (-7.07 to 7.61)       0.939         Change       1.73 ± 2.05       2.46 ± 2.66       -0.74 (-2.35 to 1.49)       0.496         95% CI       1.73 (0.28 to 3.17)       2.46 (0.58 to 4.34)       0.496         Wait/hip ratio       0.024       0.015       0.021 (-0.07 to 0.06)       0.822         After 8 wk       0.92 ± 0.02       0.004 ± 0.03       0.02 (-0.01 to 0.03)       0.02 (-0.01 to 0.04)       0.139         95% CI       0.02 (0.01 to 0.03)       0.00 (-0.02 (-0.02 to 0.02)       0.02 (-0.01 to 0.03)       0.390         P value <sup>6</sup> 0.002 (0.01 to 0.03)       0.00 (-0.00 to 0.02)       0.02 (-0.01 to 0.03)       0.390         P value <sup>6</sup> 0.002 (0.01 to 0.03)       0.01 (-0.01 to 0.02)       0.27       95% CI         Beginning       0.57 ± 0.06       0.58 ± 0.06       -0.02 (-0.07 to 0.04)       0.554         After 8 wk       0.55 ± 0.06       0.57 ± 0.06       0.02 (-0.01 to 0.02)       0.247         95% CI       0.02 (0.01 to 0.03)       0.01 (0.00 to 0.02)       0.242       0.24       0.295         P value <sup>8</sup> 0.	<i>P</i> value <sup>2)</sup>	0.002**	0.112			
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Hip circumference (cm)					
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	Beginning	$104.09 \pm 9.31$	$104.55 \pm 9.92$	-0.46 (-9.02 to 8.09)	0.911	
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	After 8 wk	$102.36 \pm 8.46$	$102.09 \pm 8.03$	0.27 (-7.07 to 7.61)	0.939	
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Change	$1.73 \pm 2.05$	$2.46 \pm 2.66$	-0.74 (-2.95 to 1.48)	0.496	
P value <sup>3</sup> 0.024 <sup>4</sup> 0.015 <sup>4</sup> Waist/hip ratio	95% CI	1.73 (0.28 to 3.17)	2.46 (0.59 to 4.34)	(		
Waist/hip ratio         Description           Beginning $0.94 \pm 0.08$ $0.95 \pm 0.07$ $-0.01 (-0.07 \text{ to } 0.06)$ $0.822$ After 8 wk $0.02 \pm 0.02$ $0.00 \pm 0.03$ $0.02 (-0.01 \text{ to } 0.04)$ $0.422$ Change $0.02 \pm 0.02$ $0.00 - (0.03 + 0.03)$ $0.02 (-0.01 \text{ to } 0.04)$ $0.139$ 95% C1 $0.006^{-1}$ $0.783$ $0.02 (-0.07 \text{ to } 0.04)$ $0.554$ Mais Meight ratio         Beginning $0.57 \pm 0.06$ $0.58 \pm 0.06$ $-0.02 (-0.07 \text{ to } 0.04)$ $0.554$ After 8 wk $0.55 \pm 0.06$ $0.51 \pm 0.06$ $0.02 (-0.07 \text{ to } 0.04)$ $0.534$ After 9 wk $0.02 \pm 0.02$ $0.01 \pm 0.03$ $0.01 (-0.01 \text{ to } 0.03)$ $0.02 (-0.07 \text{ to } 0.04)$ $0.427$ 95% C1 $0.02 \pm 0.02$ $0.01 \pm 0.03$ $0.01 (0.00 \text{ to } 0.03)$ $0.012 \text{ to } 0.03$ $0.330$ Body fat percentage (%)         Beginning $29.19 \pm 5.96$ $31.16 \pm 7.25$ $-1.97 (-7.88 \text{ to } 3.93)$ $0.493$ After 8 wk $28.06 \pm 6.39$ $30.51 \pm 7.38$ $-2.44 (-8.58 \text{ to } 3.75)$ $0.437$ <t< td=""><td>P value<sup>2)</sup></td><td>0.024*</td><td>0.015*</td><td></td><td></td></t<>	P value <sup>2)</sup>	0.024*	0.015*			
Beginning         0.94 ± 0.08         0.95 ± 0.07         -0.01 (-0.07 to 0.06)         0.822           After 8 wk         0.92 ± 0.02         0.00 ± 0.03         0.02 (-0.09 to 0.04)         0.422           Change         0.02 ± 0.02         0.00 ± 0.03         0.02 (-0.01 to 0.04)         0.139           95% CI         0.006"         0.02         0.00 ± 0.03         0.02 (-0.01 to 0.04)         0.139           Waist/height ratio           0.006"         0.02 (-0.07 to 0.04)         0.554           Mater 8 wk         0.55 ± 0.06         0.57 ± 0.06         -0.02 (-0.07 to 0.04)         0.544           After 8 wk         0.02 (0.01 to 0.03)         0.01 (0.00 to 0.03)         0.02 (-0.07 to 0.02)         0.427           95% CI         0.02 (0.01 to 0.03)         0.01 (0.00 to 0.03)         0.01 (-0.01 to 0.02)         0.427           95% CI         0.02 (0.01 to 0.03)         0.01 (0.00 to 0.03)         0.493         0.493           After 8 wk         28.06 ± 6.39         30.51 ± 7.38         -2.44 (-8.58 to 3.70)         0.417           Change         1.12 (0.28 to 1.97)         0.66 (-0.91 to 2.22)         0.47 (-1.20 to 2.13)         0.495           Body fat free mass percentage (%)         E         E         1.88 (-3.75 to 7.51)         0.495 <td>Waist/hip ratio</td> <td></td> <td></td> <td></td> <td></td>	Waist/hip ratio					
After 8 wk $0.92 \pm 0.08$ $0.95 \pm 0.06$ $-0.02 (-0.09 to 0.04)$ $0.422$ Change $0.02 \pm 0.02$ $0.00 \pm 0.03$ $0.02 (-0.01 to 0.04)$ $0.139$ $95\%$ C1 $0.02 (0.01 to 0.03)$ $0.00 (-0.02 to 0.02)$ $0.02 (-0.01 to 0.04)$ $0.139$ $95\%$ C1 $0.06^{-4}$ $0.06^{-4}$ $0.783$ $0.02 (-0.07 to 0.04)$ $0.554$ Maist/height ratio $0.57 \pm 0.06$ $0.57 \pm 0.06$ $-0.02 (-0.07 to 0.03)$ $0.390$ Change $0.02 \pm 0.02$ $0.01 \pm 0.01$ $0.01 (-0.01 to 0.02)$ $0.427$ $95\%$ C1 $0.02 (0.01 to 0.03)$ $0.01 (0.00 to 0.03)$ $0.01 (-0.01 to 0.02)$ $0.427$ $95\%$ C1 $0.02 (0.01 to 0.03)$ $0.01 (0.00 to 0.03)$ $0.01 (-0.01 to 0.02)$ $0.427$ $95\%$ C1 $0.02 (0.01 to 0.03)$ $0.01 (0.00 to 0.03)$ $0.01 (-0.01 to 0.02)$ $0.427$ $95\%$ C1 $0.02 (0.01 to 0.03)$ $0.01 (0.00 to 0.03)$ $0.01 (-0.01 to 0.02)$ $0.427$ $95\%$ C1 $1.12 (0.28 to 1.97)$ $0.66 (-2.22)$ $0.47 (-1.88 to 3.93)$ $0.493$ $After 8 wk$ $28.06 \pm 6.39$ $30.51 \pm 7.38$ $-1.97 (-7.88 to 3.93)$ $0.493$ $95\%$ C1 $1.12 (0.28 to 1.97)$ $0.66 (-0.91 to 2.22)$ $0.47 (-1.20 to 2.13)$ $0.566$ $95\%$ C1 $1.12 (0.28 to 1.97)$ $0.66 (-5.37 \pm 6.92)$ $1.88 (-3.75 to 7.51)$ $0.495$ $95\%$ C1 $-1.20 (-2.31 to -0.27)$ $-0.41 (-1.54 to 0.72)$ $0.245$ $0.245$ $95\%$ C1 $-1.20 (-2.31 to -0.27)$ $-0.41 (-1.54 to 0.72)$ $0.245$ $0.667$ <	Beginning	$0.94 \pm 0.08$	$0.95 \pm 0.07$	-0.01 (-0.07 to 0.06)	0.822	
$\begin{array}{cccc} { \mbox{Change} & 0.02 \pm 0.02 & 0.00 \pm 0.03 & 0.02 (-0.01 to 0.04) & 0.139 \\ { \mbox{Sym} Ci & 0.02 (0.01 to 0.03) & 0.00 (-0.02 to 0.02) \\ { \mbox{Pvalue}^9 & 0.006^+ & 0.783 \\ \hline \\ { \mbox{Waist/height ratio} & & & & & & & & & & & & & & & & & & &$	After 8 wk	$0.92 \pm 0.08$	$0.95 \pm 0.06$	-0.02(-0.09  to  0.04)	0.422	
S5% C1         0.00 (0.01 to 0.03) 0.000 (-0.02 to 0.02) 0.783         0.00 (-0.02 to 0.02) 0.783         0.00 (-0.02 to 0.02) 0.783           Waist/height ratio         0.000 (-0.02 to 0.02) 0.000 (-0.02 to 0.02)         0.000 (-0.02 to 0.02) 0.01 (-0.01 to 0.03) 0.01 (-0.01 to 0.03)         0.554           After 8 wk         0.55 ± 0.06         0.57 ± 0.06         -0.02 (-0.07 to 0.04)         0.554           After 9 wk         0.02 ± 0.02         0.01 ± 0.01         0.01 (-0.01 to 0.02)         0.427           95% C1         0.002 (0.01 to 0.03)         0.01 (0.00 to 0.03)         0.01 (-0.01 to 0.02)         0.427           95% C1         0.02 (0.01 to 0.03)         0.01 (0.00 to 0.03)         0.01 (-0.01 to 0.02)         0.427           Body fat percentage (%)         Beginning         29.19 ± 5.96         31.16 ± 7.25         -1.97 (-7.88 to 3.93)         0.493           After 8 wk         28.06 ± 6.33         30.51 ± 7.38         -2.44 (-8.58 to 3.70)         0.417           Change         1.12 ± 1.20         0.66 ± 2.22         0.47 (-1.20 to 2.13)         0.493           After 8 wk         68.45 ± 5.75         65.78 ± 7.23         2.67 (-3.14 to 8.48)         0.350           Change         -1.20 (-2.13 to -0.27)         -0.41 ± 1.61         -0.79 (-2.01 to 0.59)         0.245           95% C1         -1.20 (-2	Change	$0.02 \pm 0.02$	$0.00 \pm 0.03$	0.02(-0.01  to  0.04)	0.139	
P value?         0.006"         0.783           Waist/height ratio	95% CI	0.02 (0.01  to  0.03)	0.00(-0.02  to  0.02)			
Waist/height ratio       9         Beginning       0.57 ± 0.06       0.58 ± 0.06       -0.02 (-0.07 to 0.04)       0.554         After 8 wk       0.55 ± 0.06       0.57 ± 0.06       -0.02 (-0.07 to 0.03)       0.390         Change       0.02 ± 0.02       0.01 ± 0.01       0.01 (-0.01 to 0.03)       0.427         95% Cl       0.020 (0.01 to 0.03)       0.01 (0.00 to 0.03)       0.01 (-0.01 to 0.02)       0.427         9 value <sup>3</sup> 0.007"       0.112       0.01 (-0.01 to 0.02)       0.427         Body fat percentage (%)       1.12 ± 1.20       0.66 ± 2.22       0.47 (-1.20 to 2.13)       0.566         9 % Cl       1.12 ± 1.20       0.66 ± 2.22       0.47 (-1.20 to 2.13)       0.566         9 % Cl       1.12 ± 1.20       0.66 ± 2.22       0.47 (-1.20 to 2.13)       0.566         9 % Cl       1.12 ± 1.20       0.66 ± 2.22       0.47 (-1.20 to 2.13)       0.566         9 % VL       0.014'       0.372       0.914       0.372         Body fat free mass percentage (%)       1.20 (-2.21 to -0.27)       -0.41 (-1.54 to 0.72)       0.245         9 % Cl       -1.20 (-2.13 to -0.27)       -0.41 (-1.54 to 0.72)       0.245         9 % Sy Cl       -1.20 (-2.13 to -0.27)       -0.41 (-1.54 to 0.72)       0.245	P value <sup>2)</sup>	0.006**	0.783			
Beginning $0.57 \pm 0.06$ $0.58 \pm 0.06$ $-0.02 (-0.07 to 0.04)$ $0.554$ After 8 wk $0.55 \pm 0.06$ $0.57 \pm 0.06$ $-0.02 (-0.07 to 0.03)$ $0.390$ Change $0.02 \pm 0.02$ $0.01 \pm 0.01$ $0.01 (-0.01 to 0.02)$ $0.427$ 95% Cl $0.02 (0.01 to 0.03)$ $0.01 (0.00 to 0.03)$ $0.01 (-0.01 to 0.02)$ $0.427$ 95% Cl $0.007^{**}$ $0.112$ $0.01 (-0.01 to 0.02)$ $0.427$ Body fat percentage (%) $0.007^{**}$ $0.112$ $0.01 (-0.01 to 0.02)$ $0.493$ After 8 wk $28.06 \pm 6.39$ $30.51 \pm 7.38$ $-2.44 (-8.58 to 3.70)$ $0.417$ Change $1.12 \pm 1.20$ $0.66 \pm 2.22$ $0.47 (-1.20 to 2.13)$ $0.566$ 95% Cl $1.12 (0.28 to 1.97)$ $0.66 (-0.91 to 2.22)$ $0.47 (-1.20 to 2.13)$ $0.566$ 95% Cl $1.12 (0.28 to 1.97)$ $0.66 (-0.91 to 2.22)$ $0.47 (-1.20 to 2.13)$ $0.493$ After 8 wk $68.45 \pm 5.75$ $65.78 \pm 7.23$ $2.67 (-3.14 to 8.48)$ $0.350$ Change $-1.20 (-2.13 to -0.27)$ $-0.41 (-1.54 to 0.72)$ $-2.24 to 0.59$ $0.245$ 95% Cl $-1.20 (-2.13 to -0.27)$ $-0.41 (-1.54 to 0.72)$ $-2.96 to 0.59$ $0.607$ P value <sup>30</sup> $0.017^*$ $0.439$ $0.607$ $0.439$ Body mater percentage (%) $8eginning$ $51.15 \pm 3.86$ $48.95 \pm 5.58$ $2.19 (-2.07 to 6.46)$ $0.296$ After 8 wk $49.40 \pm 4.75$ $48.03 \pm 7.28$ $1.37 (-4.10 to 6.83)$ $0.607$ Change $1.74 \pm 3.79$ $0.92 \pm 4.59$	Waist/height ratio					
After 8 wk $0.55 \pm 0.06$ $0.77 \pm 0.06$ $-0.02 (-0.07 to 0.03)$ $0.390$ Change $0.02 \pm 0.02$ $0.01 \pm 0.01$ $0.01 (-0.01 to 0.02)$ $0.427$ 95% C1 $0.02 (0.01 to 0.03)$ $0.01 (0.00 to 0.03)$ $0.01 (-0.01 to 0.02)$ $0.427$ P value <sup>30</sup> $0.007^*$ $0.112$ Body fat percentage (%) $0.007^*$ $0.112$ Beginning $29.19 \pm 5.96$ $31.16 \pm 7.25$ $-1.97 (-7.88 to 3.93)$ $0.493$ After 8 wk $28.06 \pm 6.39$ $30.51 \pm 7.38$ $-2.44 (-8.58 to 3.70)$ $0.417$ Change $1.12 \pm 1.20$ $0.66 \pm 2.22$ $0.47 (-1.20 to 2.13)$ $0.566$ 95% C1 $1.12 (0.28 to 1.97)$ $0.66 (-0.91 to 2.22)$ $P$ value <sup>3</sup> $0.014^4$ $0.372$ Body fat free mass percentage (%) $Beginning$ $67.25 \pm 5.68$ $65.37 \pm 6.92$ $1.88 (-3.75 to 7.51)$ $0.495$ After 8 wk $68.45 \pm 5.75$ $65.73 \pm 7.23$ $2.67 (-3.14 to 8.48)$ $0.350$ Change $-1.20 \pm 1.32$ $-0.41 \pm 1.61$ $-0.79 (-2.16 to 0.59)$ $0.245$ 95% C1 $-1.20 (-2.13 to -0.27)$ $-0.41 (-1.54 to 0.72)$ $-0.27 (-1.34 to 6.46)$ $0.296$ After 8 wk $49.40 \pm 4.75$ $48.03 \pm 7.28$ $1.37 (-4.10 to 6.46)$ $0.296$ After 8 wk $49.40 \pm 4.75$ $48.03 \pm 7.28$ $1.37 (-4.10 to 6.46)$ $0.296$ After 8 wk $1.74 \pm 0.379$ $0.92 \pm 4.59$ $0.83 (-3.10 to 4.75)$ $0.666$ SBP (mmHg) $Beginning$ $12.26 \pm 0.50$ $12.09 \pm 1.70$ $-0.27 (-1.39 to 0.84)$ $0.620$ <	Beginning	$0.57 \pm 0.06$	$0.58 \pm 0.06$	-0.02 (-0.07 to 0.04)	0.554	
Change         0.002 ± 0.02         0.01 ± 0.01         0.01 (=0.01 to 0.02)         0.427           95% CI         0.02 (0.01 to 0.03)         0.01 (=0.01 to 0.02)         0.427           95% CI         0.007"         0.112         0           Bedy fat percentage (%)         Beginning         29.19 ± 5.96         31.16 ± 7.25         -1.97 (-7.88 to 3.93)         0.493           After 8 wk         28.06 ± 6.39         30.51 ± 7.38         -2.44 (=8.58 to 3.70)         0.417           Change         1.12 1.20         0.66 (=0.91 to 2.22)         0.47 (-1.20 to 2.13)         0.566           95% CI         1.12 (0.28 to 1.97)         0.66 (-0.91 to 2.22)         0.47 (-1.20 to 2.13)         0.566           95% CI         1.12 (0.28 to 1.97)         0.66 (=0.91 to 2.22)         0.47 (-1.20 to 2.13)         0.566           95% CI         1.12 (0.28 to 1.97)         0.66 (=0.91 to 2.22)         0.47 (-1.20 to 2.13)         0.566           95% CI         1.20 (=2.13 to -0.27)         0.41 ± 1.61         -0.79 (-2.16 to 0.59)         0.245           95% CI         -1.20 (=2.13 to -0.27)         -0.41 (=1.54 to 0.72)         0.441 ± 1.61         -0.79 (-2.16 to 0.59)         0.245           95% CI         -1.20 (=2.13 to -0.27)         -0.41 (=1.54 to 0.72)         0.666         0.296	After 8 wk	$0.55 \pm 0.06$	$0.57 \pm 0.06$	-0.02(-0.07  to  0.03)	0.390	
Instruction         Instruction         Instruction         Instruction         Instruction           95% CL         0.002 (0.01 to 0.03)         0.01 (0.00 to 0.03)         0.112           Body fat percentage (%)              Beginning         29.19 ± 5.96         31.16 ± 7.25         -1.97 (-7.88 to 3.93)         0.493           After 8 wk         28.06 ± 6.39         30.51 ± 7.38         -2.44 (-8.58 to 3.70)         0.417           Change         1.12 ± 1.20         0.66 ± 2.22         0.47 (-1.20 to 2.13)         0.566           95% Cl         1.12 (0.28 to 1.97)         0.66 (-0.91 to 2.22)             P value <sup>9</sup> 0.014*         0.372              Beginning         67.25 ± 5.68         65.37 ± 6.92         1.88 (-3.75 to 7.51)         0.495           After 8 wk         68.45 ± 5.75         65.78 ± 7.23         2.67 (-3.14 to 8.48)         0.350           Change         -1.20 (-2.13 to -0.27)         -0.41 ± 1.61         -0.79 (-2.16 to 0.59)         0.245           95% Cl         -1.20 (-2.13 to -0.27)         -0.41 (-1.54 to 0.72)         Palue <sup>9</sup> 0.017*         0.439           Body water percentage (%)         Beginning         51.15 ± 3.86 <t< td=""><td>Change</td><td><math>0.02 \pm 0.02</math></td><td><math>0.01 \pm 0.01</math></td><td>0.01 (-0.01  to  0.02)</td><td>0.427</td></t<>	Change	$0.02 \pm 0.02$	$0.01 \pm 0.01$	0.01 (-0.01  to  0.02)	0.427	
DefinitionDefinitionDefinitionP value®0.007"0.112Body fat percentage (%)29.19 ± 5.96 $31.16 \pm 7.25$ $-1.97$ ( $-7.88$ to $3.93$ )0.493After 8 wk28.06 ± 6.39 $30.51 \pm 7.38$ $-2.44$ ( $-8.58$ to $3.70$ )0.417Change $1.12 \pm 1.20$ $0.66 \pm 2.22$ $0.47$ ( $-1.20$ to $2.13$ )0.56695% Cl $1.12$ ( $0.28$ to $1.97$ ) $0.66$ ( $-0.91$ to $2.22$ ) $0.47$ ( $-1.20$ to $2.13$ )0.566P value® $0.014^*$ $0.372$ $0.47$ ( $-1.20$ to $2.13$ ) $0.495$ Body fat free mass percentage (%)Beginning $67.25 \pm 5.68$ $65.37 \pm 6.92$ $1.88$ ( $-3.75$ to $7.51$ ) $0.495$ After 8 wk $68.45 \pm 5.75$ $65.78 \pm 7.23$ $2.67$ ( $-3.14$ to $8.48$ ) $0.350$ Change $-1.20$ ( $-2.13$ to $-0.27$ ) $-0.41 \pm 1.61$ $-0.79$ ( $-2.16$ to $0.59$ ) $0.245$ 95% Cl $-1.20$ ( $-2.13$ to $-0.27$ ) $-0.41 \pm 1.61$ $-0.79$ ( $-2.16$ to $0.59$ ) $0.245$ 95% Cl $-1.20$ ( $-2.13$ to $-0.27$ ) $-0.41 \pm 1.61$ $-0.79$ ( $-2.16$ to $0.59$ ) $0.245$ 95% Cl $1.74 \pm 0.93$ to $4.475$ $48.03 \pm 7.28$ $1.37$ ( $-4.10$ to $6.83$ ) $0.607$ Change $1.74 \pm 3.79$ $0.92 \pm 4.59$ $0.83$ ( $-3.10$ to $4.75$ ) $0.666$ 95% Cl $1.74$ ( $-0.93$ to $4.42$ ) $0.92 \pm 4.59$ $0.83$ ( $-3.10$ to $4.75$ ) $0.666$ 95% Cl $0.177$ $0.541$ $5.41$ $5.88$ ( $0.71$ to $3.04$ ) $0.620$ After 8 wk $10.18 \pm 0.60$ $12.06 \pm 1.67$ $1.88$ ( $0.71$	95% CI	0.02(0.01  to  0.03)	0.01(0.00  to  0.03)	0.01 ( 0.01 to 0.02)	01127	
Body fat percentage (%) Beginning29.19 ± 5.96 $31.16 \pm 7.25$ $-1.97$ ( $-7.88$ to $3.93$ ) $0.493$ $0.493$ After 8 wk $28.06 \pm 6.39$ $30.51 \pm 7.38$ $-2.44$ ( $-8.58$ to $3.70$ ) $0.417$ $0.417$ Change $1.12 \pm 1.20$ $0.66 \pm 2.22$ $0.47$ ( $-1.20$ to $2.13$ ) $0.566$ $95\%$ Cl $1.12(0.28$ to $1.97$ ) $0.66(-0.91$ to $2.22$ ) $0.47$ ( $-1.20$ to $2.13$ ) $0.566$ $P$ value <sup>3</sup> $0.014^*$ $0.372$ $0.372$ $0.495$ Body fat free mass percentage (%) $86.45 \pm 5.75$ $65.78 \pm 7.23$ $2.67$ ( $-3.14$ to $8.48$ ) $0.350$ Change $-1.20 \pm 1.32$ $-0.41 \pm 1.61$ $-0.79$ ( $-2.16$ to $0.59$ ) $0.245$ $95\%$ Cl $-1.20(-2.13$ to $-0.27)$ $-0.41$ ( $-1.54$ to $0.72$ ) $-2.96$ $P$ value <sup>3</sup> $0.017^*$ $0.439$ $0.92 \pm 4.59$ $0.83$ ( $-3.10$ to $4.75$ )Body water percentage (%) $8eginning$ $51.15 \pm 3.86$ $48.95 \pm 5.58$ $2.19$ ( $-2.07$ to $6.46$ ) $0.296$ After 8 wk $49.40 \pm 4.75$ $48.03 \pm 7.28$ $1.37$ ( $-4.10$ to $6.83$ ) $0.607$ Change $1.74 \pm 3.79$ $0.922 \pm 4.59$ $0.83$ ( $-3.10$ to $4.75$ ) $0.666$ $95\%$ Cl $1.74$ ( $-0.93$ to $4.42$ ) $0.92$ ( $-2.32$ to $4.15$ ) $0.83$ ( $-3.10$ to $4.75$ ) $0.666$ $95\%$ Cl $0.177$ $0.541$ $0.620$ $0.004^{**}$ $0.620$ After 8 wk $10.18 \pm 0.60$ $12.06 \pm 1.67$ $1.88$ ( $0.71$ to $3.04$ ) $0.004^{**}$ Change $2.18 \pm 0.87$ $-0.03 \pm 0.22$ $-2.15$ ( $-2.75$ t	P value <sup>2)</sup>	0.007**	0.112			
Beginning29.19 ± 5.9631.16 ± 7.25-1.97 (-7.88 to 3.93)0.493After 8 wk28.06 ± 6.3930.51 ± 7.38-2.44 (-8.58 to 3.70)0.417Change1.12 ± 1.200.66 (-2.220.47 (-1.20 to 2.13)0.56695% Cl1.12 (0.28 to 1.97)0.66 (-0.91 to 2.22)0.47 (-1.20 to 2.13)0.566P value <sup>9</sup> 0.014*0.3720.5660.578 ± 7.232.67 (-3.14 to 8.48)0.350Boginning67.25 ± 5.6865.77 ± 7.232.67 (-3.14 to 8.48)0.3500.495After 8 wk68.45 ± 5.7565.78 ± 7.232.67 (-3.14 to 8.48)0.350Change-1.20 (-2.13 to -0.27)-0.41 ± 1.61-0.79 (-2.16 to 0.59)0.24595% Cl-1.20 (-2.13 to -0.27)-0.41 (-1.54 to 0.72)P value <sup>20</sup> 0.607P value <sup>20</sup> 0.017*0.4390.6070.666Beginning51.15 ± 3.8648.95 ± 5.582.19 (-2.07 to 6.46)0.296After 8 wk49.40 ± 4.7548.03 ± 7.281.37 (-4.10 to 6.83)0.607Change1.74 ± 3.790.92 ± 4.590.83 (-3.10 to 4.75)0.66695% Cl1.74 (-0.93 to 4.42)0.92 (-2.32 to 4.15)P value <sup>20</sup> 0.620P value <sup>20</sup> 0.1770.5415800.6200.622After 8 wk10.18 ± 0.6012.06 ± 1.671.88 (0.71 to 3.04)0.604**Glamma2.18 to 8.770.03 ± 0.22-2.15 (-2.75 to 1.55)< 0.001***P value <sup>20</sup> <0.001***0	Body fat percentage (%)					
After 8 wk28.06 $\pm$ 6.3930.51 $\pm$ 7.38-2.44 (-8.58 to 3.70)0.417Change1.12 $\pm$ 1.200.66 $\pm$ 2.220.47 (-1.20 to 2.13)0.56695% Cl1.12 (0.28 to 1.97)0.66 (-0.91 to 2.22)0.77 (-1.20 to 2.13)0.566P value <sup>30</sup> 0.014*0.3720.66 (-0.91 to 2.22)0.67 (-3.14 to 8.48)0.350Body fat free mass percentage (%)8 $68.45 \pm 5.75$ $65.78 \pm 7.23$ $2.67$ (-3.14 to 8.48)0.350Change-1.20 $\pm$ 1.32-0.41 $\pm$ 1.61-0.79 (-2.16 to 0.59)0.24595% Cl-1.20 (-2.13 to -0.27)-0.41 (-1.54 to 0.72)0.439Body water percentage (%)88 $9.5 \pm 5.58$ $2.19$ (-2.07 to 6.46)0.296After 8 wk49.40 $\pm$ 4.7548.03 $\pm$ 7.28 $1.37$ (-4.10 to 6.83)0.607After 8 wk1.74 $\pm$ 3.790.92 $\pm$ 4.590.83 (-3.10 to 4.75)0.66695% Cl1.74 (-0.93 to 4.42)0.92 (-2.32 to 4.15)0.83 (-3.10 to 4.75)0.66695% Cl1.74 (-0.93 to 4.42)0.92 (-2.32 to 4.15)0.83 (-3.10 to 4.75)0.66695% Cl1.74 (-0.93 to 4.42)0.92 (-2.32 to 4.15)0.88 (0.71 to 3.04)0.004**SBP (mmHg)810.18 $\pm$ 0.6012.06 $\pm$ 1.671.88 (0.71 to 3.04)0.004**Ghange2.18 $\pm$ 0.87-0.03 $\pm$ 0.22-2.15 (-2.75 to 1.55)< 0.001***	Beginning	$29.19 \pm 5.96$	$31.16 \pm 7.25$	-1.97 (-7.88 to 3.93)	0.493	
Change       1.12 ± 1.32       0.061 ± 0.02       0.47 (-1.20 to 2.13)       0.566         95% Cl       1.12 (0.28 to 1.97)       0.66 (-0.91 to 2.22)       0.47 (-1.20 to 2.13)       0.566         P value <sup>37</sup> 0.014*       0.372       0.47 (-1.20 to 2.13)       0.566         Beginning       67.25 ± 5.68       65.37 ± 6.92       1.88 (-3.75 to 7.51)       0.495         After 8 wk       68.45 ± 5.75       65.78 ± 7.23       2.67 (-3.14 to 8.48)       0.350         Change       -1.20 (-2.13 to -0.27)       -0.41 ± 1.61       -0.79 (-2.16 to 0.59)       0.245         95% Cl       -1.20 (-2.13 to -0.27)       -0.41 (-1.54 to 0.72)       P value <sup>20</sup> 0.017*       0.439         Body water percentage (%)       Beginning       51.15 ± 3.86       48.95 ± 5.58       2.19 (-2.07 to 6.46)       0.296         After 8 wk       49.40 ± 4.75       48.03 ± 7.28       1.37 (-4.10 to 6.83)       0.607         Change       1.74 (-0.93 to 4.42)       0.92 (-2.32 to 4.15)       0.541       0.541         P value <sup>20</sup> 0.177       0.541       0.541       0.520       0.620         After 8 wk       10.18 ± 0.60       12.09 ± 1.70       -0.27 (-1.39 to 0.84)       0.620         After 8 wk       10.18 ± 0.60       12.06	After 8 wk	28.06 + 6.39	30.51 + 7.38	-2.44(-8.58  to  3.70)	0.417	
95% CI       1.12 (0.28 to 1.97)       0.66 (-0.91 to 2.22)       0.014*       0.372         Body fat free mass percentage (%)       Beginning       67.25 ± 5.68       65.37 ± 6.92       1.88 (-3.75 to 7.51)       0.495         After 8 wk       68.45 ± 5.75       65.78 ± 7.23       2.67 (-3.14 to 8.48)       0.350         Change       -1.20 ± 1.32       -0.41 ± 1.61       -0.79 (-2.16 to 0.59)       0.245         95% CI       -1.20 (-2.13 to -0.27)       -0.41 (-1.54 to 0.72)       0.495         P value <sup>37</sup> 0.017*       0.439       0.439         Body water percentage (%)       Beginning       51.15 ± 3.86       48.95 ± 5.58       2.19 (-2.07 to 6.46)       0.296         After 8 wk       49.40 ± 4.75       48.03 ± 7.28       1.37 (-4.10 to 6.83)       0.607         Change       1.74 ± 3.79       0.92 ± 4.59       0.83 (-3.10 to 4.75)       0.666         95% CI       1.74 (-0.93 to 4.42)       0.92 (-2.32 to 4.15)       P value <sup>23</sup> 0.177       0.541         SBP (mmHg)       Beginning       12.36 ± 0.50       12.09 ± 1.70       -0.27 (-1.39 to 0.84)       0.620*         After 8 wk       10.18 ± 0.60       12.06 ± 1.67       1.88 (0.71 to 3.04)       0.004**         Change       2.18 ± 0.87       -0.03 ± 0.2	Change	1.12 + 1.20	$0.66 \pm 2.22$	0.47(-1.20  to  2.13)	0.566	
DefinitionDefinitionOrder is the product of the start of the	95% CI	1.12(0.28  to  1.97)	0.66(-0.91  to  2.22)	0 ( 1.120 to 1.120)	0.000	
Note:Body fat free mass percentage (%)Beginning $67.25 \pm 5.68$ $65.37 \pm 6.92$ $1.88 (-3.75 to 7.51)$ $0.495$ After 8 wk $68.45 \pm 5.75$ $65.78 \pm 7.23$ $2.67 (-3.14 to 8.48)$ $0.350$ Change $-1.20 \pm 1.32$ $-0.41 \pm 1.61$ $-0.79 (-2.16 to 0.59)$ $0.245$ $95\%$ Cl $-1.20 (-2.13 to -0.27)$ $-0.41 (-1.54 to 0.72)$ $P$ value <sup>3</sup> $0.017^*$ $0.439$ Body water percentage (%)Beginning $51.15 \pm 3.86$ $48.95 \pm 5.58$ $2.19 (-2.07 to 6.46)$ $0.296$ After 8 wk $49.40 \pm 4.75$ $48.03 \pm 7.28$ $1.37 (-4.10 to 6.83)$ $0.607$ Change $1.74 \pm 3.79$ $0.92 \pm 4.59$ $0.83 (-3.10 to 4.75)$ $0.666$ $95\%$ Cl $1.74 (-0.93 to 4.42)$ $0.92 (-2.32 to 4.15)$ $P$ value <sup>30</sup> $0.620$ Beginning $12.36 \pm 0.50$ $12.09 \pm 1.70$ $-0.27 (-1.39 to 0.84)$ $0.620$ After 8 wk $10.18 \pm 0.60$ $12.06 \pm 1.67$ $1.88 (0.71 to 3.04)$ $0.004^{**}$ Change $2.18 (1.59 to 2.77)$ $0.27 (-1.23 to 0.17)$ $P$ value <sup>30</sup> $O.001^{***}$ Value <sup>30</sup> $0.001^{***}$ $0.001^{***}$ $0.001^{***}$ $0.001^{***}$	P value <sup>2)</sup>	0.014*	0.379			
Beginning67.25 ± 5.6865.37 ± 6.921.88 (-3.75 to 7.51)0.495After 8 wk $68.45 \pm 5.75$ $65.78 \pm 7.23$ $2.67 (-3.14 to 8.48)$ $0.350$ Change $-1.20 \pm 1.32$ $-0.41 \pm 1.61$ $-0.79 (-2.16 to 0.59)$ $0.245$ 95% Cl $-1.20 (-2.13 to -0.27)$ $-0.41 (-1.54 to 0.72)$ $P$ $P$ P value <sup>3)</sup> $0.017^*$ $0.439$ $0.017^*$ $0.439$ Body water percentage (%) $Beginning$ $51.15 \pm 3.86$ $48.95 \pm 5.58$ $2.19 (-2.07 to 6.46)$ $0.296$ After 8 wk $49.40 \pm 4.75$ $48.03 \pm 7.28$ $1.37 (-4.10 to 6.83)$ $0.607$ Change $1.74 \pm 3.79$ $0.92 \pm 4.59$ $0.83 (-3.10 to 4.75)$ $0.666$ 95% Cl $1.74 (-0.93 to 4.42)$ $0.92 (-2.32 to 4.15)$ $P$ $P$ P value <sup>2)</sup> $0.177$ $0.541$ $SBP$ (mmHg) $SBP$ (mmHg) $SBP$ $SBP$ (mHg) $SBP$ $SBP$ (mHg) $SBP$ $SBP$ (mHg) $SBP$ $SBP$ $SBP$ (mHg) $SBP$ $SBP$ $SBP$	Body fat free mass percentage (%)	0.011	0.072			
After 8 wk68.45 $\pm$ 5.7565.78 $\pm$ 7.232.67 (-3.14 to 8.48)0.350Change-1.20 $\pm$ 1.32-0.41 $\pm$ 1.61-0.79 (-2.16 to 0.59)0.24595% Cl-1.20 (-2.13 to -0.27)-0.41 (-1.54 to 0.72)0.439Body water percentage (%)Beginning51.15 $\pm$ 3.8648.95 $\pm$ 5.582.19 (-2.07 to 6.46)0.296After 8 wk49.40 $\pm$ 4.7548.03 $\pm$ 7.281.37 (-4.10 to 6.83)0.607Change1.74 $\pm$ 3.790.92 $\pm$ 4.590.83 (-3.10 to 4.75)0.66695% Cl1.74 (-0.93 to 4.42)0.92 (-2.32 to 4.15)0.92 (-2.32 to 4.15)0.620P value <sup>20</sup> 0.1770.54158P(mmHg)6800.296 $\pm$ 1.671.88 (0.71 to 3.04)0.620After 8 wk10.18 $\pm$ 0.6012.06 $\pm$ 1.671.88 (0.71 to 3.04)0.004**0.004**Change2.18 $\pm$ 0.87-0.03 $\pm$ 0.22-2.15 (-2.75 to 1.55)< 0.001***	Beginning	$67.25 \pm 5.68$	$65.37 \pm 6.92$	1.88 (-3.75 to 7.51)	0.495	
Initial of the stateDefine the stateInitial of the stateInitial of the stateChange $-1.20 \pm 1.32$ $-0.41 \pm 1.61$ $-0.79$ ( $-2.16$ to $0.59$ ) $0.245$ 95% CI $-1.20$ ( $-2.13$ to $-0.27$ ) $-0.41$ ( $-1.54$ to $0.72$ ) $0.439$ Body water percentage (%)Beginning $51.15 \pm 3.86$ $48.95 \pm 5.58$ $2.19$ ( $-2.07$ to $6.46$ ) $0.296$ After 8 wk $49.40 \pm 4.75$ $48.03 \pm 7.28$ $1.37$ ( $-4.10$ to $6.83$ ) $0.607$ Change $1.74 \pm 3.79$ $0.92 \pm 4.59$ $0.83$ ( $-3.10$ to $4.75$ ) $0.666$ 95% CI $1.74$ ( $-0.93$ to $4.42$ ) $0.92$ ( $-2.32$ to $4.15$ ) $0.620$ P value <sup>20</sup> $0.177$ $0.541$ SBP (mmHg)SBP (mmHg) $12.36 \pm 0.50$ $12.09 \pm 1.70$ $-0.27$ ( $-1.39$ to $0.84$ ) $0.620$ After 8 wk $10.18 \pm 0.60$ $12.06 \pm 1.67$ $1.88$ ( $0.71$ to $3.04$ ) $0.004^{**}$ Change $2.18 \pm 0.87$ $-0.03 \pm 0.22$ $-2.15$ ( $-2.75$ to $1.55$ ) $<0.001^{***}$ 95% CI $2.18$ ( $1.59$ to $2.77$ ) $0.27$ ( $-1.23$ to $0.17$ ) $-2.15$ ( $-2.75$ to $1.55$ ) $<0.001^{***}$	After 8 wk	68.45 + 5.75	$65.78 \pm 7.93$	2.67(-3.14  to  8.48)	0.350	
DistrigoInternationOn the formationOn the formationOn the formationOn the formation95% Cl $-1.20 (-2.13 \text{ to } -0.27)$ $-0.41 (-1.54 \text{ to } 0.72)$ $0.439$ Body water percentage (%)Beginning $51.15 \pm 3.86$ $48.95 \pm 5.58$ $2.19 (-2.07 \text{ to } 6.46)$ $0.296$ After 8 wk $49.40 \pm 4.75$ $48.03 \pm 7.28$ $1.37 (-4.10 \text{ to } 6.83)$ $0.607$ Change $1.74 \pm 3.79$ $0.92 \pm 4.59$ $0.83 (-3.10 \text{ to } 4.75)$ $0.666$ 95% Cl $1.74 (-0.93 \text{ to } 4.42)$ $0.92 (-2.32 \text{ to } 4.15)$ $0.620$ P value <sup>29</sup> $0.177$ $0.541$ SBP (mmHg) $8eginning$ $12.36 \pm 0.50$ $12.09 \pm 1.70$ $-0.27 (-1.39 \text{ to } 0.84)$ $0.620$ After 8 wk $10.18 \pm 0.60$ $12.06 \pm 1.67$ $1.88 (0.71 \text{ to } 3.04)$ $0.004^{**}$ Change $2.18 \pm 0.87$ $-0.03 \pm 0.22$ $-2.15 (-2.75 \text{ to } 1.55)$ $<0.001^{***}$ 95% Cl $2.18 (1.59 \text{ to } 2.77)$ $0.27 (-1.23 \text{ to } 0.17)$ $-2.15 (-2.75 \text{ to } 1.55)$ $<0.001^{***}$	Change	$-1.20 \pm 1.32$	$-0.41 \pm 1.61$	-0.79(-2.16  to  0.59)	0.245	
P value20.017*0.439Body water percentage (%) $51.15 \pm 3.86$ $48.95 \pm 5.58$ $2.19 (-2.07 \text{ to } 6.46)$ $0.296$ After 8 wk $49.40 \pm 4.75$ $48.03 \pm 7.28$ $1.37 (-4.10 \text{ to } 6.83)$ $0.607$ Change $1.74 \pm 3.79$ $0.92 \pm 4.59$ $0.83 (-3.10 \text{ to } 4.75)$ $0.666$ 95% CI $1.74 (-0.93 \text{ to } 4.42)$ $0.92 (-2.32 \text{ to } 4.15)$ $0.666$ 95% CI $0.177$ $0.541$ SBP (mmHg)Beginning $12.36 \pm 0.50$ $12.09 \pm 1.70$ $-0.27 (-1.39 \text{ to } 0.84)$ $0.620$ After 8 wk $10.18 \pm 0.60$ $12.06 \pm 1.67$ $1.88 (0.71 \text{ to } 3.04)$ $0.004^{**}$ Change $2.18 \pm 0.87$ $-0.03 \pm 0.22$ $-2.15 (-2.75 \text{ to } 1.55)$ $<0.001^{***}$ 95% CI $2.18 (1.59 \text{ to } 2.77)$ $0.27 (-1.23 \text{ to } 0.17)$ $<0.001^{***}$ $<0.001^{***}$	95% CI	$-1.20 \pm 1.32$	-0.41(-1.54  to  0.72)	0.75 ( 2.10 to 0.55)	0.245	
I vitte0.10170.105Body water percentage (%)Beginning $51.15 \pm 3.86$ $48.95 \pm 5.58$ $2.19 (-2.07 \text{ to } 6.46)$ $0.296$ After 8 wk $49.40 \pm 4.75$ $48.03 \pm 7.28$ $1.37 (-4.10 \text{ to } 6.83)$ $0.607$ Change $1.74 \pm 3.79$ $0.92 \pm 4.59$ $0.83 (-3.10 \text{ to } 4.75)$ $0.666$ $95\%$ CI $1.74 (-0.93 \text{ to } 4.42)$ $0.92 (-2.32 \text{ to } 4.15)$ $-0.27 (-1.39 \text{ to } 0.84)$ $0.662$ $P$ value <sup>2</sup> $0.177$ $0.541$ SBP (mmHg)Beginning $12.36 \pm 0.50$ $12.09 \pm 1.70$ $-0.27 (-1.39 \text{ to } 0.84)$ $0.620$ After 8 wk $10.18 \pm 0.60$ $12.06 \pm 1.67$ $1.88 (0.71 \text{ to } 3.04)$ $0.004^{**}$ Change $2.18 \pm 0.87$ $-0.03 \pm 0.22$ $-2.15 (-2.75 \text{ to } 1.55)$ $<0.001^{***}$ $95\%$ CI $2.18 (1.59 \text{ to } 2.77)$ $0.27 (-1.23 \text{ to } 0.17)$ $-2.15 (-2.75 \text{ to } 1.55)$ $<0.001^{***}$ $95\%$ CI $2.18 (1.59 \text{ to } 2.77)$ $0.27 (-1.23 \text{ to } 0.17)$ $-2.15 (-2.75 \text{ to } 1.55)$ $<0.001^{***}$	$P \text{ value}^{2}$	0.017*	0.439			
Beginning $51.15 \pm 3.86$ $48.95 \pm 5.58$ $2.19 (-2.07 \text{ to } 6.46)$ $0.296$ After 8 wk $49.40 \pm 4.75$ $48.03 \pm 7.28$ $1.37 (-4.10 \text{ to } 6.83)$ $0.607$ Change $1.74 \pm 3.79$ $0.92 \pm 4.59$ $0.83 (-3.10 \text{ to } 4.75)$ $0.666$ $95\%$ CI $1.74 (-0.93 \text{ to } 4.42)$ $0.92 (-2.32 \text{ to } 4.15)$ $0.83 (-3.10 \text{ to } 4.75)$ $0.666$ $95\%$ CI $0.177$ $0.541$ $0.92 (-2.32 \text{ to } 4.15)$ $0.27 (-1.39 \text{ to } 0.84)$ $0.620$ SBP (mmHg) $8eginning$ $12.36 \pm 0.50$ $12.09 \pm 1.70$ $-0.27 (-1.39 \text{ to } 0.84)$ $0.620$ After 8 wk $10.18 \pm 0.60$ $12.06 \pm 1.67$ $1.88 (0.71 \text{ to } 3.04)$ $0.004^{**}$ Change $2.18 \pm 0.87$ $-0.03 \pm 0.22$ $-2.15 (-2.75 \text{ to } 1.55)$ $<0.001^{***}$ $95\%$ CI $2.18 (1.59 \text{ to } 2.77)$ $0.27 (-1.23 \text{ to } 0.17)$ $-2.15 (-2.75 \text{ to } 1.55)$ $<0.001^{***}$ $95\%$ CI $2.18 (1.59 \text{ to } 2.77)$ $0.27 (-1.23 \text{ to } 0.17)$ $-2.15 (-2.75 \text{ to } 1.55)$ $<0.001^{***}$ $92\%$ $<0.001^{***}$ $0.695$ $0.695$ $<0.001^{***}$ $0.695$	Body water percentage (%)	0.017	0.100			
After 8 wk $49.40 \pm 4.75$ $48.03 \pm 7.28$ $1.37 (-4.10 \text{ to } 6.83)$ $0.607$ Change $1.74 \pm 3.79$ $0.92 \pm 4.59$ $0.83 (-3.10 \text{ to } 4.75)$ $0.666$ $95\%$ CI $1.74 (-0.93 \text{ to } 4.42)$ $0.92 (-2.32 \text{ to } 4.15)$ $0.83 (-3.10 \text{ to } 4.75)$ $0.666$ $95\%$ CI $0.177$ $0.541$ SBP (mmHg) $12.36 \pm 0.50$ $12.09 \pm 1.70$ $-0.27 (-1.39 \text{ to } 0.84)$ $0.620$ After 8 wk $10.18 \pm 0.60$ $12.06 \pm 1.67$ $1.88 (0.71 \text{ to } 3.04)$ $0.004^{**}$ Change $2.18 \pm 0.87$ $-0.03 \pm 0.22$ $-2.15 (-2.75 \text{ to } 1.55)$ $<0.001^{***}$ $95\%$ CI $2.18 (1.59 \text{ to } 2.77)$ $0.27 (-1.23 \text{ to } 0.17)$ $-2.15 (-2.75 \text{ to } 1.55)$ $<0.001^{***}$ $9 \text{ value}^{29}$ $<0.001^{***}$ $0.695$ $<0.001^{***}$ $0.695$ $<0.001^{***}$	Beginning	51 15 + 3 86	48 95 + 5 58	2 19 (-2 07 to 6 46)	0.296	
Alter 6 with $4.4.0 \pm 1.75$ $40.60 \pm 1.26$ $1.67 (-4.10 \pm 0.60)$ $0.607$ Change $1.74 \pm 3.79$ $0.92 \pm 4.59$ $0.83 (-3.10 \pm 0.60)$ $0.666$ $95\%$ CI $0.177$ $0.92 (-2.32 \pm 0.4.15)$ $0.666$ $P$ value <sup>2)</sup> $0.177$ $0.541$ SBP (mmHg) $12.36 \pm 0.50$ $12.09 \pm 1.70$ $-0.27 (-1.39 \pm 0.84)$ $0.620$ After 8 wk $10.18 \pm 0.60$ $12.06 \pm 1.67$ $1.88 (0.71 \pm 0.04)$ $0.004^{**}$ Change $2.18 \pm 0.87$ $-0.03 \pm 0.22$ $-2.15 (-2.75 \pm 0.155)$ $<0.001^{***}$ $95\%$ CI $2.18 (1.59 \pm 0.2.77)$ $0.27 (-1.23 \pm 0.17)$ $-2.15 (-2.75 \pm 0.155)$ $<0.001^{***}$ $P$ value <sup>2)</sup> $<0.001^{***}$ $0.695$ $<0.001^{***}$ $0.695$	After 8 wk	49 40 + 4 75	48 03 + 7 28	1.37(-4.10  to  6.83)	0.200	
1.74±0.375       0.02±4.35       0.03(-3.10 t0 4.75)       0.000         95% CI       1.74 (-0.93 to 4.42)       0.92 (-2.32 to 4.15)       0.05 (-3.10 t0 4.75)       0.000         P value <sup>2</sup> 0.177       0.541       0.5541       0.620         SBP (mmHg)       10.18 ± 0.60       12.09 ± 1.70       -0.27 (-1.39 to 0.84)       0.620         After 8 wk       10.18 ± 0.60       12.06 ± 1.67       1.88 (0.71 to 3.04)       0.004**         Change       2.18 ± 0.87       -0.03 ± 0.22       -2.15 (-2.75 to 1.55)       < 0.001***	Change	1 74 + 3 79	$-9.03 \pm 7.20$	0.83(-3.10 to 4.75)	0.666	
P value <sup>2)</sup> 0.177       0.3210 4.137         SBP (mmHg)       12.36 ± 0.50       12.09 ± 1.70       -0.27 (-1.39 to 0.84)       0.620         After 8 wk       10.18 ± 0.60       12.06 ± 1.67       1.88 (0.71 to 3.04)       0.004**         Change       2.18 ± 0.87       -0.03 ± 0.22       -2.15 (-2.75 to 1.55)       < 0.001***		$1.74 \pm 3.73$	$0.92 \pm 4.39$	0.03 (-3.10 to 4.73)	0.000	
SBP (mmHg)     12.36 ± 0.50     12.09 ± 1.70     -0.27 (-1.39 to 0.84)     0.620       After 8 wk     10.18 ± 0.60     12.06 ± 1.67     1.88 (0.71 to 3.04)     0.004**       Change     2.18 ± 0.87     -0.03 ± 0.22     -2.15 (-2.75 to 1.55)     < 0.001***	P value <sup>2)</sup>	1.7+ (-0.93 t0 4.42) Ο 177	0.52 (-2.52 (0 4.15)			
Beginning $12.36 \pm 0.50$ $12.09 \pm 1.70$ $-0.27$ ( $-1.39$ to 0.84) $0.620$ After 8 wk $10.18 \pm 0.60$ $12.06 \pm 1.67$ $1.88$ ( $0.71$ to $3.04$ ) $0.004^{**}$ Change $2.18 \pm 0.87$ $-0.03 \pm 0.22$ $-2.15$ ( $-2.75$ to $1.55$ ) $< 0.001^{***}$ 95% CI $2.18$ ( $1.59$ to $2.77$ ) $0.27$ ( $-1.23$ to $0.17$ ) $< 0.001^{***}$ $P$ value <sup>20</sup> $< 0.001^{***}$ $0.695$ $< 0.695$	SRP (mmHg)	0.1/7	0.341			
After 8 wk         10.18 ± 0.60         12.05 ± 1.70         -0.27 (-1.35 to 0.84)         0.620           After 8 wk         10.18 ± 0.60         12.06 ± 1.67         1.88 (0.71 to 3.04)         0.004**           Change         2.18 ± 0.87         -0.03 ± 0.22         -2.15 (-2.75 to 1.55)         < 0.001***	Beginning	19 36 + 0 50	12 09 + 1 70	-0.97(-1.39 + 0.084)	0.620	
Change     2.18 ± 0.87     -0.03 ± 0.22     -2.15 (-2.75 to 1.55)     < 0.001***       95% CI     2.18 (1.59 to 2.77)     0.27 (-1.23 to 0.17)          P value <sup>2)</sup> < 0.001***	After 8 wk	$12.30 \pm 0.30$	$12.03 \pm 1.70$	$1.88(0.71 \pm 0.204)$	0.020	
95% Cl     2.16 ± 0.07     -0.03 ± 0.22     -2.15 (-2.75 to 1.55)     < 0.001		$10.10 \pm 0.00$	$12.00 \pm 1.07$	1.00(0.71(0.3.04))	< 0.004	
P value <sup>2)</sup> < 0.001 <sup>***</sup> 0.695		$2.10 \pm 0.87$	$-0.03 \pm 0.22$ 0.97 (-1.92 to 0.17)	-2.13 (-2.75 (0 1.55)	0.001	
	P value <sup>2)</sup>	< 0.001***	0.695			

(continued to the next page)

Table 3. (Continued) The anthropometric measurements of PPB- and SB-consuming individuals measured calculated at the beginning and after 8 wk of the intervention

Variables	Gro	ups	95% CI	P value <sup>1)</sup>
	PPB (n = 11)	SB (n = 11)		
DBP (mmHg)				
Beginning	8.09 ± 0.54	$7.91 \pm 0.70$	-0.18 (-0.74 to 0.37)	0.504
After 8 wk	$6.64 \pm 0.67$	$7.96 \pm 0.27$	1.32 (0.85 to 1.80)	< 0.001***
Change	$1.45 \pm 0.69$	$-0.05 \pm 0.44$	-1.51 (-2.02 to 0.99)	< 0.001***
95% CI	1.45 (0.99 to 1.92)	-0.05 (-0.35 to 0.24)		
<i>P</i> value <sup>2)</sup>	< 0.001***	0.690		

Data are presented as mean  $\pm$  SD.

PPB, pomegranate peel-added bread consumers; SB, standard bread consumers; CI, confidence interval; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure.

<sup>1)</sup>Independent samples *t*-test; <sup>2)</sup>Paired *t*-test. \**P* < 0.05, \*\**P* < 0.01, \*\*\**P* < 0.001.

Table 4. Metabolic and oxidative stress parameters of PPB- and SB-consuming individuals measured at the beginning and after 8 weeks of the intervention

Variables	Gro	oups	95% CI	P value <sup>1)</sup>	
	PPB (n = 11)	SB (n = 11)	-		
FBG (mg/dL)					
Beginning	$137.00 \pm 37.01$	$143.18 \pm 48.49$	-6.18 (-44.55 to 32.19)	0.740	
After 8 wk	$127.09 \pm 36.28$	$135.45 \pm 20.92$	-8.36 (-34.7 to 17.98)	0.515	
Change	$9.91 \pm 44.14$	$7.73 \pm 35.92$	2.18 (-35.36 to 39.72)	0.905	
95% CI	9.91 (-21.19 to 41.01)	7.73 (-17.58 to 33.04)	,		
P value <sup>2)</sup>	0.494	0.512			
HbA1c (%)					
Beginning	$6.85 \pm 1.54$	$6.89 \pm 1.33$	-0.04 (-1.32 to 1.24)	0.948	
After 8 wk	$6.50 \pm 1.65$	$6.70 \pm 1.10$	-0.20 (-1.44 to 1.05)	0.746	
Change	$0.34 \pm 1.28$	$0.19 \pm 0.53$	0.15 (-0.76 to 1.07)	0.728	
95% CI	0.34 (-0.56 to 1.24)	0.19(-0.19  to  0.56)	( , ,		
P value <sup>2)</sup>	0.418	0.289			
Insulin (uU/mL)					
Beginning	$13.35 \pm 7.46$	$12.34 \pm 7.07$	-0.16 (-6.24 to 5.91)	0.956	
After 8 wk	$11.18 \pm 6.22$	$13.01 \pm 8.91$	-0.88 (-7.65 to 5.88)	0.789	
Change	2.18 + 2.31	$-0.67 \pm 4.74$	2.85(-0.79  to  6.49)	0.116	
95% CI	2 18 (0.24  to  4.11)	-0.67 (-4.01 to 2.66)	2100 ( 0170 10 0110)	01220	
P value <sup>2)</sup>	0.032*	0.663			
HOMA-IB (mIU/L)	0.002	0.000			
Beginning	4 09 + 9 39	4 45 + 3 97	-0.36 (-2.91 to 2.18)	0 770	
After 8 wk	$3.69 \pm 1.87$	4 38 + 3 03	-0.69(-2.93  to  1.54)	0.526	
Change	0.40 + 2.03	0.07 + 9.46	0.03(-1.77  to  9.44)	0.320	
	$0.4(1.09 \pm 2.03)$	$0.07 \pm 2.40$	0.33 (-1.77 to 2.44)	0.740	
	0.4 (-1.02 to 1.83)	0.07 (-1.00 to 1.81)			
Total-C (mg/dL)	0.342	0.327			
Poginning	200.00 + 48.07	904 99 ± 45 92	$1.97(49.90 \pm 0.20.75)$	0.040	
After 9 wik	191.00 ± 43.37	$204.82 \pm 43.83$	-1.27(-42.29(0)39.73)	0.949	
Change	$181.00 \pm 43.71$	$202.10 \pm 43.35$	-15.00(-53.8710(23.87))	0.430	
	$20.00 \pm 21.32$	$2.04 \pm 29.24$	25.36 (0.19 (0.35)	0.046	
	28.00 (10.17 to 45.82)	2.64 (-17.96 t0 23.24)			
P Value <sup>-7</sup>	0.008	0.781			
HDL-C (ING/GL)	45 72 . 0 50		$0.07(0.15 \pm 0.70)$	0.050	
After Quel	45.73 ± 9.52	45.45 ± 11.58	0.27 (-9.15 to 9.70)	0.952	
Aller 8 WK	44.18 ± 8.00	44.45 ± 9.61	-0.27 (-8.41 to 7.86)	0.945	
Change	$1.55 \pm 6.18$	1.00 ± 3.22	0.55 (-4.05 to 5.14)	0.807	
95% CI	1.55 (-2.81 to 5.90)	1.00 (-1.27 to 3.27)			
P value <sup>2</sup>	0.448	0.349			
LDL-C (mg/dL)		101 00 41 01		0.500	
Beginning	$114.73 \pm 43.17$	121.09 ± 41.91	-6.36 (-44.21 to 31.48)	0.729	
After 8 wk	$111.27 \pm 42.00$	$126.82 \pm 42.77$	-15.55 (-53.25 to 22.16)	0.400	
Change	3.45 ± 23.31	$-5.73 \pm 25.65$	9.18 (-13.68 to 32.04)	0.412	
95% CI	3.45 (-12.97 to 19.88)	-5.73 (-23.8 to 12.35)			
P value <sup>2)</sup>	0.649	0.496			

(continued to the next page)

Table 4. (Continued) Metabolic and oxidative stress parameters of PPB- and SB-consuming individuals measured at the beginning and after 8 weeks of the intervention

Variables	Gro	ups	95% CI	P value <sup>1)</sup>
	PPB (n = 11)	SB (n = 11)	-	
TG (mg/dL)				
Beginning	215.09 ± 70.54	$191.36 \pm 50.19$	23.73 (-30.72 to 78.17)	0.374
After 8 wk	$158.91 \pm 46.98$	$163.64 \pm 55.69$	-4.73 (-50.55 to 41.10)	0.832
Change	$56.18 \pm 48.69$	27.73 ± 36.44	28.45 (–11.66 to 68.57)	0.155
95% CI	56.18 (21.88 to 90.49)	27.73 (2.05 to 53.4)		
P value <sup>2)</sup>	0.004**	0.137		
TAC (mmol/L)				
Beginning	ginning 1.53 ± 0.24		0.01 (-0.17 to 0.19)	0.899
After 8 wk	$1.60 \pm 0.25$	$1.55 \pm 0.30$	0.01 (-0.24 to 0.26)	0.933
Change	$-0.07 \pm 0.14$	$-0.03 \pm 0.17$	0.00 (-0.15 to 0.15)	0.990
95% CI	-0.07 (-0.17 to 0.03)	-0.03 (-0.19 to 0.05)		
P value <sup>2)</sup>	0.146	0.214		
TBARS (mmol/L)				
Beginning 4.55 ± 0.99		$3.72 \pm 0.34$	0.83 (-2.94 to 4.61)	0.650
After 8 wk	$3.90 \pm 0.57$	$4.28 \pm 0.13$	-0.38 (-4.31 to 3.55)	0.843
Change	$0.65 \pm 1.38$	$-0.56 \pm 1.73$	1.21 (-0.25 to 2.67)	0.099
95% CI	0.65 (-0.32 to 1.62)	-0.56 (-1.78 to 0.66)		
P value <sup>2)</sup>	0.166	0.329		

Data are presented as mean  $\pm$  SD.

PPB, pomegranate peel-added bread consumers; SB, standard bread consumers; CI, confidence interval; FBG, fasting blood glucose; HOMA, homeostatic model of insulin resistance; Total-C, total cholesterol; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; TG, triglyceride; TAC, total antioxidant capacity; TBARS, thiobarbituric acid reactive substances.

<sup>1)</sup>Independent samples *t*-test; <sup>2)</sup>Paired *t*-test.

\*P < 0.05, \*\*P < 0.01.

#### Table 5. Sensory parameters of breads

Breads	Crust color	Bread inner color	Flavor	Odor	Hardness	Pore structure	Chewability	General taste
S	$3.6 \pm 1.1$	$3.8 \pm 1.0$	$3.5 \pm 1.1$	$3.6 \pm 0.9$	$3.8 \pm 0.9$	$3.9 \pm 0.4$	$3.9 \pm 0.6$	$3.7 \pm 0.4$
PP	$4.1 \pm 1.3$	$4.3 \pm 0.7$	$4.4 \pm 0.9^{*}$	$\textbf{4.4} \pm \textbf{0.7}^{*}$	$4.4 \pm 1.2$	$4.0 \pm 0.6^{*}$	$4.0 \pm 0.6^{*}$	$4.3 \pm 0.6$

Data are presented as mean  $\pm$  SD.

S, standard; PP, pomegranate peel.

\*P < 0.05.

## **Results of biochemical parameters**

On examining the inter-group comparison results of the metabolic and oxidative stress parameters measured at the beginning of the study and after 8 wk of intervention, we found that the changes in serum cholesterol values measured after 8 wk of intervention were significantly higher in individuals who consumed PPB than in individuals who consumed SB (P < 0.05). When the intra-group comparison results were assessed, serum insulin, cholesterol, and TG levels of the individuals who consumed PPB were found to be significantly higher at the beginning of the study than after 8 wk of the intervention (P < 0.05) (Table 4).

## **DISCUSSION**

In this study, 8 wk of PPB consumption by individuals with type 2 diabetes had a positive effect on anthropometric measurements and on biochemical parameters such as serum insulin, total cholesterol, TG, and blood pressure levels, suggesting that pomegranate peels may play a protective role against type 2 diabetes and its complications.

Hyperglycemia is a characteristic of type 2 diabetes; it creates a chronic proinflammatory condition that reduces the antioxidant potential of cells by promoting ROS production,



oxidative stress, and proinflammatory cytokine production [7]. The increasing prevalence of type 2 diabetes and awareness regarding healthy nutrition and decline in food reserves have resulted in consumers wanting to benefit from food in terms of health and nutrition, increasing their tendency toward functional foods, especially those made with by-products of fruits [8,24,25]. The pomegranate peel, which is one of these by-products, contains many bioactive compounds such as phenolic compounds, flavonoids, and polyphenols, including hydrolyzable tannins, dietary fiber, vitamins, and minerals [26]. While the content of bioactive compounds in pomegranate peels tends to be higher than that in edible parts, the complex compounds are usually present as a mixture in pomegranate peels; thus, the synergistic effect of the different compounds can also induce various physiological effects [27]. Numerous *in vivo* and *in vitro* studies have suggested using the antioxidant and antiinflammatory effects of these compounds as a strategy for preventing and managing type 2 diabetes and its complications that have an inflammatory basis because they can significantly reduce the negative effects of ROS and nitrogen species on physiological functions [28,29].

Rather than body weight and BMI, waist circumference has been shown to be an independent factor of chronic diseases, especially type 2 diabetes and obesity [30]. Decreases in waist circumference may also reduce the risk of type 2 diabetes, even though body weight and BMI remain constant [31]. In contrast, oxidative stress is associated with an increased BMI and waist circumference [32]. Individuals with increased BMI and waist circumference may have impaired antioxidant defense systems, lower antioxidant concentrations, increased lipid peroxidation levels, and increased cytokine release from adipose tissue [33]. Studies conducted to assess the relationship between anthropometric measurements and antioxidant capacity found a negative relationship between dietary TAC values with BMI and central adiposity values [34,35]. In contrast, a study conducted in Iran found that individuals with higher dietary antioxidant capacities had a higher waist circumference and waist/hip ratios [32]. Studies emphasize that fruits and vegetables are the main sources of antioxidants and fiber [36,37], by-products considered waste products are also sources of antioxidants and fiber [27,38], and consumption of these by-products may be effective in reducing anthropometric measurements [39]. A study conducted in Mexico concluded that an increase in fiber consumption had a positive effect on BMI and fat mass and lean mass levels of the participants. The mechanism underlying these effects may be because the increase in fiber consumption caused a decrease in body fat tissue by lowering the glycemic index and increasing insulin sensitivity [40,41]. In a study aiming to examine the effect of consuming pomegranate peels, which are a by-product, on anthropometric measurements, 500 mg of pomegranate peel extract was administered to individuals with type 2 diabetes for 8 wk; this caused a significant decrease in the waist circumference of the individuals [9]. In a recent study, 1,000 mg of pomegranate extract was administered to obese individuals who participated in the study for a month, and at the end of the study, the BMI did not significantly differ between the group that was administered pomegranate extract and the control group; however, the treatment group experienced greater weight loss [42]. In a study conducted with 20 obese individuals who consumed 120 mL of pomegranate juice or placebo for 4 wk, those who consumed pomegranate juice had greater reductions in body weight, BMI, and body fat than those who consumed placebo [43]. In a prospective cohort study conducted in the Netherlands, a positive correlation was found between the total dietary antioxidant capacity and fat-free mass of participants, which was attributed to the increase in proinflammatory cytokines related to oxidative stress, leading to protein degradation, atrophy, and loss of muscle fibers [44]. In our study, the waist circumference, waist/hip ratio, waist/height ratio, and body fat percentage of individuals consuming pomegranate peels were



significantly lower than those in the control group, whereas the fat-free mass percentage was significantly higher (P < 0.05) (**Table 3**). Although various studies have shown that gallic acid in pomegranates suppresses appetite by increasing adiponectin levels and decreasing leptin levels, the total energy intake of individuals did not differ significantly between both groups in this study; these results can be explained by the high antioxidant capacity and fiber content of pomegranate peels [45]. In addition, the consumption of pomegranate peel significantly reduced SBP and DBP (P < 0.05) (**Table 3**). These results are congruent with those of previous studies, and possible mechanisms are as follows: 1) the consumption of polyphenols obtained from pomegranates decreases angiotensin-converting enzyme levels and increases the bioavailability of nitric oxide, which has a vasodilatory effect on blood vessels [46] or 2) fiber consumption reduces arterial BP by reducing body weight, blood lipid levels, and glycemia [47,48].

Ensuring glycemic control is indispensable for type 2 diabetes management [1]. In this study, the decrease in FBG and HOMA-IR levels in individuals with type 2 diabetes was not statistically significant (P > 0.05); however, serum insulin levels were significantly decreased (P<0.05) (Table 4). In vitro studies have demonstrated the underlying mechanisms, wherein gallic acid, a phenolic compound in pomegranates, increases the activity of the glucose transporter peroxisome proliferator-activated receptor gamma (PPAR-γ) [49], and ellagic acid, another phenolic compound, decreases resistin levels [50], both of which result in reduced insulin resistance. High fiber and phenolic compound levels in pomegranate peels are associated with improved glycemic control [37]. This effect may be a result of dietary fibers reducing or delaying carbohydrate absorption, inhibiting increases in insulin levels, and improving glycemic control [39,51]. In clinical studies carried out with individuals with type 2 diabetes, Banihani *et al.* [2] found that pomegranate juice use increased  $\beta$ -cell function, Grabež et al. [9] found that pomegranate peel consumption decreased serum insulin levels, and Sohrab et al. [52] found that 12 wk of pomegranate juice supplementation did not have an effect on glycemic markers. Considering the results of previous studies, the lack of a significant effect of pomegranate peels on FBG and insulin resistance in the current study can be explained by the small sample size. In addition, the relationship between central obesity and increased insulin levels in type 2 diabetes is well known [53]. This suggests that the decrease in serum insulin levels may be due to the antioxidant capacity and fiber content of the pomegranate peel as well as the decrease in waist circumference and body fat percentage of individuals consuming the pomegranate peel.

Individuals with type 2 diabetes have a two to three times higher prevalence of cardiovascular disease than individuals without type 2 diabetes [54]. Most individuals with type 2 diabetes have dyslipidemia, which is characterized by increased TG and LDL cholesterol levels and decreased HDL cholesterol levels [6]. In the present study, pomegranate peel consumption decreased serum TG, total cholesterol, and LDL cholesterol levels and increased HDL cholesterol levels in individuals with type 2 diabetes; however, among these parameters, only TG and total cholesterol levels were significant (P < 0.05) (**Table 4**). In studies evaluating the effects of pomegranate peels on lipid metabolism, the one possible mechanism is linked to polyphenol components, where in polyphenols in pomegranate peels reduce serum TG and total cholesterol levels by inhibiting pancreatic lipase activity and acetyl-coenzyme A acetyltransferase and 3-hydroxy-3-methylglutaryl coenzyme A reductase enzymes [55]. Additionally, among the pomegranate peel polyphenols [56], punicalagin suppresses TG biosynthesis through the enzyme diacylglycerol acyltransferase 1 [57] ellagic acid causes a dose-dependent improvement, in the lipid profile, punicic acid reduces inflammation and



improves metabolic processes depending on PPAR- $\gamma$ , which is the main modulator of lipid metabolism[58], catalpic acid reduces serum TG levels in white adipose tissue through PPAR- $\gamma$ , and gallic acid reduces serum total cholesterol and TG levels [59]. While both animal model and clinical studies have shown that the use of polyphenols reduces serum LDL cholesterol levels and LDL oxidation and increases HDL cholesterol levels, some studies have detected no effects [59,60]. Apart from the polyphenols in the pomegranate peel, other compounds reportedly have effects on lipid metabolism and oxidation, for example, fat-soluble flavonoids adhering to membranes of lipoprotein particles and reducing lipid peroxidation [61]. TBARS values are usually measured as markers of lipid peroxidation [9]. Studies on pomegranates and their by-products have found that their antioxidant capacity increases depending on the polyphenols they contain, which are responsible for the development of limited oxidative damage [62.63]. In our study, TBARS values decreased by 14.2% in the pomegranate peel–consuming group and increased by 18.6% in the control group; however, these values were not statistically significant (P > 0.05) (Table 4). TAC values increased by 4.5% in the group consuming pomegranate peels and by 1.9% in the control group, and this difference was also not significant (P > 0.05). The fact that the consumption of antioxidant minerals and vitamins by the participants was similar before and after the study suggests that this difference between the groups could be attributed to the pomegranate peel. This result is inconsistent with those of studies conducted with individuals with type 2 diabetes and metabolic syndrome [17,64]. The antioxidant activity of the both pomegranate peel and breads was measured with the 1,1-diphenyl-2-picrylhydrazyl and 2,2'-Azino-bis (3-ethylbenzothiazoline-6-sulfonic acid) tests, which are widely used to evaluate free radical scavenging ability. The values obtained were consistent with those of previous studies [65,66] and showed a strong antioxidant activity in our study. Apart from the high polyphenol content of the pomegranate peel, the lipid profile is also associated with the high fiber content. For instance, dietary fibers increase the fecal excretion of bile acids, reduce cholesterol absorption, and cause fat malabsorption [67]. Studies indicate a negative relationship between dietary fiber consumption and plasma cholesterol and TG levels [51,68]. While the decrease in total cholesterol and TG levels is attributed to the polyphenol and fiber content of the pomegranate peel, these differences between our study results and those from the literature in terms of LDL cholesterol levels, TBARS values, and TAC can be attributed to the small sample size, dose [9,24], shape [12,14], and heat treatment of the pomegranate peel [69].

In products with a high antioxidant capacity, heat treatment decreases their capacity [70]. Although no previous studies have been conducted on heat-treated pomegranate peels, in a study on black corn with high anthocyanin levels and some phenolic compounds, heat treatment was associated with a significant decrease in both compounds [71]. Similarly, the anthocyanin content of wheat breads made with blue and purple grains decreased after baking [72]. Contrary to these study results, another study determined that phenolic compounds maintain their antioxidant properties after baking, which provides potential benefits to consumers [73].

Sensory characteristics are important parameters in bread consumption and affect the quality of the final product [74]. Altunkaya *et al.* [75] evaluated the sensory properties of PPB and showed that the addition of pomegranate peels (2.5%, 5%, and 10%) to bread formulations did not affect the acceptability of the breads in general. In another study in which the sensory evaluation of PPB was performed in terms of color, aroma, texture, taste, and mouthfeel, only the hardness of the BPP was disliked, compared with that of the white



bread (control) [76]. In this study, the PPB sample was more favorable than the SB in terms of all the evaluated sensory parameters. However, among these sensory parameters, the difference was statistically significant in terms of flavor, odor, chewability, and pore structure (P < 0.05) (**Table 5**).

The strengths of this study include the use of PPB, since pomegranate peels are usually seen as a waste product, of both laboratory and clinical stages, of interviews being conducted face-to-face, and of a randomized and double-blind design to avoid selection bias. This study also has limitations that should be acknowledged. The first limitation was the small sample size, which led to a limited number of individuals being evaluated. Another limitation is the inability to provide sufficient power to investigate the effects of other factors, such as age and body weight, which affects the generalizability of the results.

In conclusion, the pomegranate peel, which is rich in polyphenols, has positive effects on anthropometric measurements and serum insulin levels, lipid profiles, and blood pressure levels in individuals with type 2 diabetes. The addition of pomegranate peels did not have a negative effect on the sensory properties of the PPB. On the basis of the results, we believe that fruit waste products such as pomegranate peels, especially those rich in polyphenols and fibers, can be used in healthy and safe products suitable for our consumption. Despite a partial loss in antioxidant activity due to heat treatment, these products can be implemented in strategies to manage type 2 diabetes and play a preventive role in the development of complications. In addition, bioactive components such as polyphenols and fibers contained in pomegranate peels can be used as functional components. With the development of functional foods rich in antioxidant capacity and fiber, waste products can be evaluated and sustainable nutrition can be promoted, as with the development of PPB in our study. Considering the results of this study, well-designed randomized controlled studies with larger sample sizes, longer dose-controlled intervention times, and individuals of different ages and BMI values are needed to confirm the beneficial effects of pomegranate peels in the management of type 2 diabetes in the future.

## ACKNOWLEDGMENTS

We would like to thank all the individuals for their cooperation who participated in our study.

## REFERENCES

- 1. International Diabetes Federation. IDF Diabetes Atlas 10th Edition 2021 [Internet]. Brussels: IDF; 2021 [cited 2022 April 10]. Available from: https://idf.org/e-library/epidemiology-research/diabetes-atlas.html.
- 2. Banihani S, Swedan S, Alguraan Z. Pomegranate and type 2 diabetes. Nutr Res 2013;33:341-8. PUBMED | CROSSREF
- Lewis GF, Carpentier A, Adeli K, Giacca A. Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr Rev 2002;23:201-29.
   PUBMED | CROSSREF
- Kyrou I, Tsigos C. Obesity in the elderly diabetic patient: is weight loss beneficial? Diabetes Care 2009;32 Suppl 2:S403-9.
   PUBMED | CROSSREF
- Williams K, Tchernof A, Hunt KJ, Wagenknecht LE, Haffner SM, Sniderman AD. Diabetes, abdominal adiposty, and atherogenic dislipoproteinemia in women compared with men. Diabetes 2008;57:3289-96.
   PUBMED | CROSSREF



- Parhofer KG. Interaction between glucose and lipid metabolism: more than diabetic dyslipidemia. Diabetes Metab J 2015;39:353-62.
   PUBMED | CROSSREF
- Preedy RV. Diabetes: Oxidative stress and dietary antioxidants. In: Preddy VR, editor. Diabetes: Oxidative Stress and Dietary Antioxidants. London: Academic Press; 2020. p.36-41.
- Green M, Arora K, Prakash S. Microbial Medicine: Prebiotic and probiotic functional foods to target obesity and metabolic syndrome. Int J Mol Sci 2020;21:2890.
   PUBMED | CROSSREF
- Grabež M, Škrbić R, Stojiljković MP, Rudić-Grujić V, Paunović M, Arsić A, Petrovic S, Vucic V, Mirjanic-Azaric B, Savikin K, et al. Beneficial effects of pomegranate peel extract on plasma lipid profile, fatty acids levels and blood pressure in patients with diabetes mellitus type-2: a randomized, double-blind, placebocontrolled study. J Funct Foods 2020;64:103692.
   CROSSREF
- Viuda-Martos M, Fernández-López J, Pérez-Álvarez JA. Pomegranate and its many functional components as related to human health: a review. Compr Rev Food Sci Food Saf 2010;9:635-54.
   PUBMED | CROSSREF
- Çam M, İçyer NC, Erdoğan F. Pomegranate peel phenolics: Microencapsulation, storage stability and potential ingredient for functional food development. Lebensm Wiss Technol 2014;55:117-23.
   CROSSREF
- Akhtar S, Ismail T, Fraternale D, Sestili P. Pomegranate peel and peel extracts: chemistry and food features. Food Chem 2015;174:417-25.
   PUBMED | CROSSREF
- Singh RP, Chidambara Murthy KN, Jayaprakasha GK. Studies on the Antioxidant activity of pomegranate (*Punicagranatum*) peel and seed extracts using *in vitro* models. J Agric Food Chem 2002;50:81-6.
   PUBMED | CROSSREF
- Naveena BM, Sen AR, Vaithiyanathan S, Babji Y, Kondaiah N. Comparative efficacy of pomegranate juice, pomegranate rind powder extract and BHT as antioxidants in cooked chicken patties. Meat Sci 2008;80:1304-8.
   PUBMED | CROSSREF
- Kanatt SR, Chander R, Sharma A. Antioxidant and antimicrobial activity of pomegranate peel extract improves the shelf life of chicken products. Int J Food Sci Technol 2010;45:216-22.
   CROSSREF
- 16. Jakobek L. Interactions of polyphenols with carbohydrates, lipids and proteins. Food Chem 2015;175:556-67.
- Aviram M, Dornfeld L, Rosenblat M, Volkova N, Kaplan M, Coleman R, Hayek T, Presser D, Fuhrman B. Pomegranate juice consumption reduces oxidative stress, atherogenic modifications to LDL, and platelet aggregation: studies in humans and in atherosclerotic apolipoprotein E-deficient mice. Am J Clin Nutr 2000;71:1062-76.

PUBMED | CROSSREF

- World Health Organization. Pericarpium Granati. WHO Monographs on Selected Medicinal Plants. 42009 [Internet]. Geneva: WHO; 2006 [cited 2022 February 10]. Available from: https://apps.who.int/iris/ handle/10665/42052.
- 19. Rakıcıoğlu NT, Ayaz A, Pekcan G. Food and Food Photo Catalogue, Sizes and Quantities. Ankara: Nadir Press; 2012.
- 20. Merdol TK. Standard Food Recipes for Instituons With Mass Nutrition. Ankara: Hatipoğlu Press; 2003.
- Schmind M. Beslenme Bilgi Sistemi BEBİS 8.2 Paket program [Internet]. Struttgart: Entwickelt an der Universital Hohenheim; 2011 [cited 2022 February 10]. Available from: https://www.bebis.com.tr.
- 22. Pekcan G. Determination of nutritional status. In: Baysal A, Aksoy M, Besler T, editors. Diet Handbook. Ankara: Hatipoğlu Press; 2013. p.67-141.
- 23. Ashwell M, Gibson S. Waist-to-height ratio as an indicator of 'early health risk': simpler and more predictive than using a 'matrix' based on BMI and waist circumference. BMJ Open 2016;6:e010159. PUBMED | CROSSREF
- Grabež M, Škrbić R, Stojiljković MP, Vučić VM, Grujić VR, Jakovljević V, Djuric DM, Surucic R, Savikin K, Bigovic D, et al. A prospective, randomized, double-blind, placebo-controlled trial of polyphenols on the outcomes of inflammatory factors and oxidative stress in patients with type 2 diabetes mellitus. Rev Cardiovasc Med 2022;23:57.
   PUBMED | CROSSREF
- El-Hadary AE, Ramadan MF. Phenolic profiles, antihyperglycemic, antihyperlipidemic, and antioxidant properties of pomegranate (*Punica granatum*) peel extract. J Food Biochem 2019;43:e12803.
   PUBMED | CROSSREF



- 26. Singh B, Singh JP, Kaur A, Singh N. Phenolic compounds as beneficial phytochemicals in pomegranate (*Punica granatum* L.) peel: a review. Food Chem 2018;261:75-86.
  PUBMED | CROSSREF
- Guil-Guerrero JL, Ramos L, Moreno C, Zúñiga-Paredes JC, Carlosama-Yepez M, Ruales P. Plant foods byproducts as sources of health-promoting agents for animal production: a review focusing on the tropics. Agron J 2016;108:1759-74.
- 28. Dietary Reference Intakes for Vitamin C. Vitamin E, Selenium, and Carotenoids. Washington DC: National Academies Press; 2000. p.35-58.
- 29. Yoon JH, Baek SJ. Molecular targets of dietary polyphenols with anti-inflammatory properties. Yonsei Med J 2005;46:585-96.

## PUBMED | CROSSREF

- Amato MC, Guarnotta V, Giordano C. Body composition assessment for the definition of cardiometabolic risk. J Endocrinol Invest 2013;36:537-43.
   PUBMED | CROSSREF
- Luo W, Guo Z, Hu X, Zhou Z, Wu M, Zhang L, Liu J. 2 years change of waist circumference and body mass index and associations with type 2 diabetes mellitus in cohort populations. Obes Res Clin Pract 2013;7:e290-6.
   PUBMED | CROSSREF
- 32. Azizi-Soleiman F, Khoshhali M, Heidari-Beni M, Qorbani M, Kelishadi R. Association between dietary antioxidant quality score and anthropometric measurements in children and adolescents: The weight disorders survey of the CASPIAN-IV Study. J Trop Pediatr 2021;67:fmaa065. PUBMED | CROSSREF
- Vincent HK, Taylor AG. Biomarkers and potential mechanisms of obesity-induced oxidant stress in humans. Int J Obes (Lond) 2006;30:400-18.
   PUBMED | CROSSREF
- Puchau B, Ochoa MC, Zulet MA, Marti A, Martínez JA, Members G. Dietary total antioxidant capacity and obesity in children and adolescents. Int J Food Sci Nutr 2010;61:713-21.

  PUBMED I CROSSREF
- 35. Hermsdorff HH, Puchau B, Volp AC, Barbosa KB, Bressan J, Zulet MÁ, Martínez JA. Dietary total antioxidant capacity is inversely related to central adiposity as well as to metabolic and oxidative stress markers in healthy young adults. Nutr Metab (Lond) 2011;8:59. PUBMED | CROSSREF
- 36. Yadav A, Kumari R, Yadav A, Mishra JP, Srivastava S, Prabha S. Antioxidants and its functions in human body: a review. Res Environ Life Sci 2016;9:1328-31.
- Rampersaud GC, Valim MF. 100% citrus juice: nutritional contribution, dietary benefits, and association with anthropometric measures. Crit Rev Food Sci Nutr 2017;57:129-40.
   PUBMED | CROSSREF
- Bhargava A. Fiber intakes and anthropometric measures are predictors of circulating hormone, triglyceride, and cholesterol concentrations in the women's health trial. J Nutr 2006;136:2249-54.
   PUBMED | CROSSREF
- Järvi A, Karlström B, Vessby B, Becker W. Increased intake of fruits and vegetables in overweight subjects: effects on body weight, body composition, metabolic risk factors and dietary intake. Br J Nutr 2016;115:1760-8.
   PUBMED | CROSSREF
- Velázquez-López L, Santiago-Díaz G, Nava-Hernández J, Muñoz-Torres AV, Medina-Bravo P, Torres-Tamayo M. Mediterranean-style diet reduces metabolic syndrome components in obese children and adolescents with obesity. BMC Pediatr 2014;14:175.
   PUBMED | CROSSREF
- Al-Muammar MN, Khan F. Obesity: the preventive role of the pomegranate (*Punica granatum*). Nutrition 2012;28:595-604.
   PUBMED | CROSSREF
- Hosseini B, Saedisomeolia A, Wood LG, Yaseri M, Tavasoli S. Effects of pomegranate extract supplementation on inflammation in overweight and obese individuals: A randomized controlled clinical trial. Complement Ther Clin Pract 2016;22:44-50.
   PUBMED | CROSSREF
- 43. González-Ortiz M, Martínez-Abundis E, Espinel-Bermúdez MC, Pérez-Rubio KG. Effect of pomegranate juice on insulin secretion and sensitivity in patients with obesity. Ann Nutr Metab 2011;58:220-3. PUBMED | CROSSREF



- van der Schaft N, Trajanoska K, Rivadeneira F, Ikram MA, Schoufour JD, Voortman T. Total dietary antioxidant capacity and longitudinal trajectories of body composition. Antioxidants (Basel) 2020;9:728.
   PUBMED | CROSSREF
- 45. Singh RP, Chidambara Murthy KN, Jayaprakasha GK. Studies on the antioxidant activity of pomegranate (*Punica granatum*) peel and seed extracts using *in vitro* models. J Agric Food Chem 2002;50:81-6.
  PUBMED | CROSSREF
- 46. Asgary S, Sahebkar A, Afshani MR, Keshvari M, Haghjooyjavanmard S, Rafieian-Kopaei M. Clinical evaluation of blood pressure lowering, endothelial function improving, hypolipidemic and antiinflammatory effects of pomegranate juice in hypertensive subjects. Phytother Res 2014;28:193-9. PUBMED | CROSSREF
- 47. Stockton A, Farhat G, McDougall GJ, Al-Dujaili EA. Effect of pomegranate extract on blood pressure and anthropometry in adults: a double-blind placebo-controlled randomised clinical trial. J Nutr Sci 2017;6:e39.
  - PUBMED | CROSSREF
- Aleixandre A, Miguel M. Dietary fiber and blood pressure control. Food Funct 2016;7:1864-71.
   PUBMED | CROSSREF
- Francis GA, Annicotte JS, Auwerx J. PPAR agonists in the treatment of atherosclerosis. Curr Opin Pharmacol 2003;3:186-91.
   PUBMED | CROSSREF
- Makino-Wakagi Y, Yoshimura Y, Uzawa Y, Zaima N, Moriyama T, Kawamura Y. Ellagic acid in pomegranate suppresses resistin secretion by a novel regulatory mechanism involving the degradation of intracellular resistin protein in adipocytes. Biochem Biophys Res Commun 2012;417:880-5.
   PUBMED | CROSSREF
- Chandalia M, Garg A, Lutjohann D, von Bergmann K, Grundy SM, Brinkley LJ. Beneficial effects of high dietary fiber intake in patients with type 2 diabetes mellitus. N Engl J Med 2000;342:1392-8.
   PUBMED | CROSSREF
- Sohrab G, Nasrollahzadeh J, Zand H, Amiri Z, Tohidi M, Kimiagar M. Effects of pomegranate juice consumption on inflammatory markers in patients with type 2 diabetes: A randomized, placebocontrolled trial. J Res Med Sci 2014;19:215-20.
- Bonneau GA, Pedrozo WR, Berg G. Adiponectin and waist circumference as predictors of insulinresistance in women. Diabetes Metab Syndr 2014;8:3-7.
   PUBMED | CROSSREF
- 54. Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di Angelantonio E, Ingelsson E, Lawror DA, Selvin E, Stampfer E, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 2010;375:2215-22.
  PUBMED | CROSSREF
- 55. Abdel-Rahim E, El-Beltagi H, Romela R. White bean seeds and Pomegranate peel and fruit seeds as hypercholesterolemic and hypolipidemic agents in albino rats. Grasas Aceites 2013;64:50-8. CROSSREF
- Rosenblat M, Aviram M. Pomegranate juice protects macrophages from triglyceride accumulation: inhibitory effect on DGAT1 activity and on triglyceride biosynthesis. Ann Nutr Metab 2011;58:1-9.
   PUBMED | CROSSREF
- 57. Lv O, Wang L, Li J, Ma Q, Zhao W. Effects of pomegranate peel polyphenols on lipid accumulation and cholesterol metabolic transformation in L-O2 human hepatic cells via the PPARγ-ABCA1/CYP7A1 pathway. Food Funct 2016;7:4976-83.
  PUBMED | CROSSREF
- 58. Hontecillas R, Diguardo M, Duran E, Orpi M, Bassaganya-Riera J. Catalpic acid decreases abdominal fat deposition, improves glucose homeostasis and upregulates PPAR α expression in adipose tissue. Clin Nutr 2008;27:764-72.
  PURMED I CROSSREE
- Jang A, Srinivasan P, Lee NY, Song HP, Lee JW, Lee M, Jo C. Comparison of hypolipidemic activity of synthetic gallic acid-linoleic acid ester with mixture of gallic acid and linoleic acid, gallic acid, and linoleic acid on high-fat diet induced obesity in C57BL/6 Cr Slc mice. Chem Biol Interact 2008;174:109-17.
   PUBMED | CROSSREF
- Sahebkar A, Simental-Mendia LE, Giorgini P, Ferri C, Grassi D. Lipid profile changes after pomegranate consumption: a systematic review and meta-analysis of randomized controlled trials. Phytomedicine 2016;23:1103-12.
   PUBMED | CROSSREF



- 61. Grassi D, Desideri G, Ferri L, Tiberti S, Ferri C. Cocoa and lipid profile: a fat paradox? Agro Food Ind Hi Tech 2009;20:23-5.
- Guo C, Wei J, Yang J, Xu J, Pang W, Jiang Y. Pomegranate juice is potentially better than apple juice in improving antioxidant function in elderly subjects. Nutr Res 2008;28:72-7.
   PUBMED | CROSSREF
- 63. Petrovic S, Arsic A, Glibetic M, Cikiriz N, Jakovljevic V, Vucic V. The effects of polyphenol-rich chokeberry juice on fatty acid profiles and lipid peroxidation of active handball players: results from a randomized, double-blind, placebo-controlled study. Can J Physiol Pharmacol 2016;94:1058-63.
  PUBMED | CROSSREF
- 64. Kojadinovic MI, Arsic AC, Debeljak-Martacic JD, Konic-Ristic AI, Kardum ND, Popovic TB, Glibetic MD. Consumption of pomegranate juice decreases blood lipid peroxidation and levels of arachidonic acid in women with metabolic syndrome. J Sci Food Agric 2017;97:1798-804. PUBMED I CROSSREF
- 65. Ardekani MR, Hajimahmoodi M, Oveisi MR, Sadeghi N, Jannat B, Ranjbar AM, Gholam N, Moridi T. Comparative antioxidant activity and total flavonoid content of Persian pomegranate (*Punica granatum* L.) cultivars. Iran J Pharm Res 2011;10:519-24.
- 66. Tehranifar A, Selahvarzi Y, Kharrazi M, Bakhsh VJ. High potential of agro-industrial by-products of pomegranate (*Punica granatum* L.) as the powerful antifungal and antioxidant substances. Ind Crops Prod 2011;34:1523-7. CROSSREF
- López-Marcos MC, Bailina C, Viuda-Martos M, Pérez-Alvarez JA, Fernández-López J. Properties of dietary fibers from agroindustrial coproducts as source for fiber-enriched foods. Food Bioprocess Technol 2015;8:2400-8.
   CROSSREF
- 68. Xu X, Zhang J, Zhang Y, Qi H, Wang P. Associations between dietary fiber intake and mortality from all causes, cardiovascular disease and cancer: a prospective study. J Transl Med 2022;20:344.
  PUBMED | CROSSREF
- Başlar M, Ertugay MF. Effect of ultrasound and photosonication treatment on polyphenoloxidase (PPO) activity, total phennolic component and colour of apple juice. Int J Food Sci Technol 2013;48:886-92.
   CROSSREF
- Topçu B, Caba ZT, Erdil DN. Effect of oat bread production stages on phenolic content and antioxidant activity. Food Health 2019;5:48-63.
   CROSSREF
- Sablani SS, Marcotte M, Baik OD, Castaigne F. Modeling of Simultaneous heat and water transport in the baking process. Lebensm Wiss Technol 1998;31:201-9.
- Eliášová M, Kotíková Z, Lachman J, Orsák M, Martinek P. Influence of baking on anthocyanin content in coloured-grain wheat bread. Plant Soil Environ 2020;66:381-6.
   CROSSREF
- 73. Han HM, Koh BK. Antioxidant activity of hard wheat flour, dough and bread prepared using various processes with the addition of different phenolic acids. J Sci Food Agric 2011;91:604-8.
  PUBMED | CROSSREF
- Hobbs RJ, Higgs E, Hall CM, Bridgewater P, Chapin FS, Ellis EC, Ewel JJ, Hallett M, Harris J, Hulvey KB, et al. Managing the whole landscape: historical, hybrid, and novel ecosystems. Front Ecol Environ 2014;12:557-64.
   CROSSREF
- 75. Altunkaya A, Hedegaard RV, Brimer L, Gökmen V, Skibsted H. Antioxidant capacity versus chemical safety of wheat bread enriched with pomegranate peel powder. Food Funct 2013;4:722-7.
  PUBMED | CROSSREF
- 76. Srivastava P, Indrani D, Singh RP. Effect of dried pomegranate (*Punica granatum*) peel powder (DPPP) on textural, organoleptic and nutritional characteristics of biscuits. Int J Food Sci Nutr 2014;65:827-33.
  PUBMED | CROSSREF